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ABSTRACT 
Introduction and purpose 
The aim of the study was to determine the renal handling of a once-off bolus dietary 
protein load in patients treated for nephroblastoma.  Patients who have been 
managed for nephroblastoma always have suboptimal amounts of kidney tissue as a 
result of their medical management which includes nephrectomies, chemotherapy 
and or radiotherapy.  Little data are available indicating the extent of renal 
impairment expected in such patients as a result of their disease and management.  
The study was to determine whether the use of regular screening tests such as 
serum urea, creatinine and urine microalbumin, in conjunction with a dietary protein 
load could help detect early progressive deterioration of kidney function in 
nephroblastoma patients. 
Methodology 
The study was a quantitative non-randomised intervention study in which patients 
served as their own control before and after a protein load. 
 Thirty-four participants were included in the study.  Each participant was provided 
with a supplemental protein drink providing 2 g/kg body weight of protein.  Serum 
creatinine, urea and urine microalbumin were assessed at baseline and four hours 
after the intervention. These pre- and post intervention biochemical values were then 
analysed together with descriptive data relating to the participants, such as age, 
stage of nephroblastoma, aspects of medical management and the period of time 
since they had been treated for nephroblastoma, and statistical relationships were 
assessed. Data were collected from May 2010 to November 2010. 
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Results 
Descriptive statistics indicated that the mean [± Standard deviation (SD)] age of the 
population was 92 (± 55) months, the mean age at diagnosis was 41 (± 27) months 
and the mean age from the diagnosis to the time of the study was 51 (± 53) months.  
There was a statistically significant increase (p = 0.00) in serum urea post 
intervention; however, no significant difference was noted between pre- and post 
intervention serum creatinine and urine microalbumin values.  The stages of 
nephroblastoma failed to show a statistical correlation with the response to the 
dietary protein bolus load in terms of the difference in pre- and post intervention 
biochemical data.  No statistical correlation was found between post-pubescence and 
response to the protein load. Similiarly, no statistical correlation could be 
demonstrated for a longer period between the diagnosis and the time of this study, 
on the one hand, and the prevalence of high values in the biochemical data, on the 
other. 
Conclusion 
The study was unable to demonstrate statistically that participants managed for 
nephroblastoma had poor renal handling of a once-off dietary protein load in terms of 
the objectives specified.  The study had limitations including a small population with 
even smaller subgroups of participants, therefore results of the study need to be 
interpreted in context to the size of the population.   
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OPSOMMING 
Doel 
Die doel van die studie was om die renale hantering van ’n eenmalige bolus 
dieetproteïenlading by pasiënte wat vir nefroblastoom behandel word, te bepaal.  
Pasiënte wat vir nefroblastoom behandel word, het altyd ‘n subopitmale hoeveelheid 
nierweefsel as gevolg van hulle mediese behandeling wat nefrektomies, 
chemoterapie en / of radioterapie insluit.  Min data is beskikbaar omtrent die omvang 
van die nierbelemmering wat in sulke pasiënte verwag word as gevolg van hulle 
siekte en behandeling.  Die studie is uitgevoer om te bepaal of die gebruik van 
gereelde siftingstoetse soos serum-ureum, kreatinien en mikroalbuminurie, in 
samewerking met ‘n dieetproteïenlading, kan help om vroeë progressiewe 
agteruitgang van nierfunksie in nefroblastoom pasiënte, op te spoor. 
Metodologie 
Die studie was ‘n kwantitatiewe nie-ewekansige intervensie studie waar  pasiënte as 
hul eie kontrole gedien het voor en na ‘n proteïenlading.  Altesaam 34 deelnemers is 
by die studie betrek. Elke deelnemer het ’n proteïenaanvullingsdrankie ontvang wat 
2 gram proteïen per kilogram liggaamsgewig voorsien het. Serumkreatinien, serum-
ureum en mikro-albuminurie is op die basislyn sowel as vier uur na die intervensie 
gemeet. Hierdie biochemiese waardes voor en na die intervensie is daarna saam 
met beskrywende data van die deelnemers – soos ouderdom, stadium van 
nefroblastoom, aspekte van mediese behandeling en tydsverloop sedert behandeling 
vir nefroblastoom – ontleed. Statistiese verwantskappe is vervolgens beoordeel. Data 
is vanaf Mei 2010 tot November 2010 ingesamel. 
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Resultate 
Beskrywende statistieke het op ’n gemiddelde [± Standaard afwyking (SA)] 
populasie-ouderdom van 92 (± 55) maande, ’n gemiddelde diagnose-ouderdom van 
41(± 27) maande en ’n gemiddelde ouderdom van 51(± 53) maande vanaf diagnose 
tot en met die studie gedui.  Ná die intervensie is ’n statisties beduidende toename 
(p = 0.00) in serum-ureum opgemerk, hoewel daar geen beduidende verskil in 
serumkreatinien en mikro-albuminurie waardes, voor en na behandeling, was nie. 
Biochemiese data voor en na die intervensie het geen statistiese verwantskap tussen 
die stadium van nefroblastoom en die reaksie op die dieetproteïenlading getoon nie. 
Boonop is geen statistiese verwantskap opgemerk tussen post-pubesensie en die 
reaksie op die proteïenlading, of tussen ’n langer tydsverloop tussen die diagnose en 
die studie en die voorkoms van hoë waardes in die biochemiese data nie.   
Gevolgtrekking 
Wat die studie-doelwitte betref, kon die navorsing nie statisties bewys dat 
deelnemers wat vir nefroblastoom behandel word, swak renale hantering van ’n 
eenmalige dieetproteïenlading toon nie.  Die beperkinge van die studie sluit ‘n klein 
populasie met selfs kleiner subgroepe in; die resultate van die studie moet derhalwe 
in die konteks van die grootte van die populasie, geÏnterpreteer word. 
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LIST OF DEFINITIONS1 
Anthropometry The taking of measurements of the human body or its parts. 
Comparisons can then be made among individuals of different 
sexes, ages and races to distinguish between normal and 
abnormal development. 
Body Mass Index The weight of a person (in kilograms) divided by the square of 
the height of that person (in meters): used as an indicator of 
whether or not a person is over- or underweight 
Chemotherapy The prevention or treatment of disease by the use of chemical 
substances. 
Creatinine A product of protein metabolism found in muscle. 
Glomerular 
filtration rate 
The rate at which substances are filtered from the blood of the 
glomeruli into the Bowman’s capsules of the nephrons.  It is 
calculated by measuring the clearance of specific substances 
and is an index of renal function. 
Microalbuminuria The presence of albumin in the urine at levels that are higher 
than normal but lower than those detected bystandard protein 
dipsticks. 
Nephroblastoma 
(Wilms’tumour) 
A malignant tumour arising from the embryonic kidney and 
occurring in young children usually below the age of three and 
rarely over the age of eight. 
Puberty The time at which the onset of sexual maturity occurs and the 
reproductive organs become functional. This is manifested by 
the appearance of secondary sexual characteristics 
(menstruation and breast development in girls and deepening 
of the voice in boys). 
Radiotherapy The treatment of disease with penetrating radiation, such a X-
rays, beta rays or gamma rays, which may be produced by 
machines or given off by radioactive isotopes. 
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Urea The main breakdown product of protein metabolism. It is the 
chemical form in which unrequired nitrogen is excreted by the 
body in the urine. Accumulation of urea in the bloodstream 
together with other nitrogenous compounds is due to kidney 
failure and gives rise to uraemia. 
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1.1 INTRODUCTION 
The departments of Paediatric Surgery and Dietetics at Inkosi Albert Luthuli Central 
Hospital (IALCH) are actively involved in the management of all paediatric solid 
tumours.  Patients are diagnosed, treated, followed up and monitored for 
recurrences, other developing conditions, general health and growth by the 
Department of Paediatric Surgery, which has a large data set accessible for further 
studies.  This database of patients presents wonderful opportunities for studies on 
the nephroblastoma population of KwaZulu-Natal (KZN) and outlying areas.  The 
primary researcher was actively involved in the nutritional management of children 
with solid tumours at IALCH.  The opportunity to study this patient population further 
with a passionate team of doctors inspired the interest in assessing the patients’ 
renal functions in response to a dietary protein load.  With the support of both the 
Paediatric Surgery and Dietetics departments, this study was initiated in 2008 and 
data gathering was completed by the end of 2010. 
1.2 PROBLEM STATEMENT 
Patients managed for nephroblastoma undergo unilateral, total or partial 
nephrectomy, as well as chemotherapy and/or radiotherapy,2 all of which reduce the 
functioning renal cell mass.  Patients who have been managed for nephroblastoma 
always have suboptimal amounts of kidney tissue although it is known that patients 
with a solitary kidney develop hypertrophy of the remaining kidney in an attempt to 
compensate for the workload of the kidney that was surgically removed.  During 
periods of rapid growth such as puberty and pregnancy, kidneys are placed under 
increased pressure physiologically.  Currently, little data are available indicating the 
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extent of renal impairment expected in such patients, especially after periods of 
increased growth. 
It is necessary to determine which patients who have been managed for 
nephroblastoma are at a high risk of developing renal impairment later in life, 
especially during times of physiological stress.  It was therefore decided to determine 
whether the use of regular screening tests such as serum urea, creatinine and urine 
microalbumin could help detect early progressive deterioration of kidney function in 
nephroblastoma patients. 
Establishing that one can use routine biochemical data such as microalbumin as a 
screening tool for renal impairment in patients with nephroblastoma may enable 
physicians to identify patients who will require more detailed assessment of kidney 
function.  Renal function of patients managed for nephroblastoma is usually 
assessed by tools such as the glomerular filtration rate (GFR), renal plasma flow 
(RPF) and tubular sodium (Na) transport studies.3  Such investigations are valid tools 
but they are expensive and invasive, making them inappropriate for use as screening 
tools. The aim of this study was to see whether a simple test such as the effect of a 
dietary protein load on renal function (investigating the change in patients’ serum 
urea, creatinine and urine microalbumin) could identify subgroups in the 
nephroblastoma population who were at risk for renal impairment. 
1.3 ASSUMPTIONS AND DELIMITATION 
Based on the knowledge and experience gained in working with the population of 
patients who attended IALCH, the following generalisations were made: 
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 That patients attending the clinic came from middle- to low-income 
backgrounds with some families depending on government care grants as 
their only source of income. 
 That the majority of patients attending the clinic were ethnic Africans. 
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2.1 INTRODUCTION 
Nephroblastoma, more commonly known as Wilms’ tumour, is a common renal solid 
tumour of childhood.2  It was first described by Max Wilms in Germany in 1899.  
Initially, surgery was the only means of treatment for these patients, and the overall 
survival rate was approximately 20%.  However, with the introduction of radiotherapy 
in the 1940s, the survival rate improved to 50%, and finally with the introduction of 
chemotherapy in the 1960s, the survival rate for patients managed for 
nephroblastoma increased to > 85% in first world countries.3,4 Wilms’ tumour is now 
one of the most successfully treated cancers of childhood.5 
2.2 TUMOUR ORIGIN 
Nephroblastomas are known to arise from embryonic renal tissue, in the renal 
parenchyma.2,4  A Wilms’ tumour has a triphasic appearance, presenting with three 
different cell lines (epithelial cells, blastemal cells and mesenchymal).  Some 
histological variants such as Wilms’ tumour with an anaplastic appearance carry a 
poor prognosis.2,6 
Nephroblastomatosis, which is a complex abnormality of nephrogenesis, results in 
the finding of nephrogenic rests (embryonic renal tissue) within an otherwise normal 
kidney.2,7 These embryonic metanephric tissue remnants may be found in 1% of 
normal children, 35% of patients presenting with unilateral Wilms’ tumour and in all 
patients presenting with bilateral renal tumours.2,4 
Several individual genetic anomalies as well as rare genetic syndromes have been 
associated with Wilms’ tumour.  Such syndromes include WAGR syndrome, Denys-
Drash syndrome, Beckwith-Wiedemann syndrome and Perlman syndrome.2,4 
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In the United Kingdom, the Wilms’ Tumour Screening Working Group suggests that 
patients with significant risk factors for Wilms’ tumour be referred to a clinical 
geneticist to attempt to determine or estimate the risk of developing 
nephroblastoma.2 
2.3 INCIDENCE 
There has been considerable variation in the reported incidence of nephroblastoma; 
however, it appears to be more prevalent amongst people of ethnic African origin, 
both in the developed world and in developing countries.2  An article in the British 
Journal of Cancer in 2002 suggested that nephroblastoma had an incidence rate of 1 
in 10 000 live births.6  However, a 2007 article by G.S. Arul indicated that the annual 
incidence of Wilms’ tumour in the United Kingdomwas 0.8 per 100 000 population.2 
Wilms’ tumour usually presents between the ages of two and seven years, with a 
median age at presentation of 42 months.  Approximately 90% of all patients are 
under the age of eight years.2,4,6 
Of patients presenting with Wilms’ tumour, only approximately 4–7% have bilateral 
tumours.  Patients with bilateral tumours are generally diagnosed earlier than 
patients with unilateral tumours.  Furthermore, patients with bilateral tumours are 
more likely to be associated with developmental delays and abnormalities.2,8  A South 
African study on the clinical presentation of Wilms’ tumour reflected the distribution of 
the population in KZN in 1990.  Out of 48 patients, 35 lived in rural areas, compared 
to 13 from urban areas, and it was indicated that rural patients had larger tumours 
than urban patients.  Thirty-one percent of the patients included in this study had 
tumours > 10% of their pre-operative body mass.9  The male:female ratio was 0.92 for 
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unilateral tumours and 0.6 for bilateral tumours10; however, other papers present the 
ratio as equal.2,4 Wilms’ tumour has a higher incidence in black populations than 
white populations, with a threefold higher incidence.8,10 Furthermore, children in less 
developed nations have been seen to present with more advanced disease than 
children in first world countries.10 
2.4 PRESENTATION 
Nephroblastomais usually diagnosed after parents see and feel a hard abdominal 
mass in their child.2,4  The mass is usually unaccompanied by other symptoms; 
however, fever is present in approximately 20% of patients and nonspecific 
abdominal complains are seen in 10%.4  The tumour may be discovered as a result of 
screening for a predisposing sign, such as variococoele, or because of the side 
effects of tumour bleeding.  These include: anaemia, haematuria, abdominal pain 
and raised temperature.2,4 
2.5 STAGING 
Nephroblastoma has been classified by the International Society of Pediatric 
Oncology (SIOP) and the National Wilms’ Tumor Study (NWTS) into five different 
stages (see Table 2.1).4,10 
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Table 2.1: Wilms’ tumour classification2,4,10 
Stage Classification 
I Tumour limited to the kidney, completely excised 
II Tumour extending outside the kidney, completely excised 
Invasion beyond the capsule, perirenal/perihilar 
Invasion of extrarenal vessels 
Invasion of ureter if completely excised 
III Invasion beyond capsule, excision incomplete 
Invasion to the regional lymph nodes 
Per-/preoperative tumour rupture 
Peritoneal metastases 
IV Distant haematogenous metastases 
V Synchronous or metachronous bilateral renal tumours 
 
2.6 TREATMENT 
There are two approaches to the treatment of nephroblastoma: the Childrens 
Oncology Group (COG) (having succeeded the NWTS in the United States of 
America [USA]) and the SIOP approaches.  The NWTS focused on primary 
nephrectomy, followed by chemotherapy with or without radiotherapy, depending on 
the stage and histology of the tumour.4 The SIOP approach, an adaptation of which is 
used in IALCH in KZN, recommends initial chemotherapy treatment, followed by 
surgical removal of the tumour.  The European SIOP approach is widely used in 
South Africa as the majority of the tumours presented are extremely large and often 
already at Stage III or Stage IV.  The SIOP approach is beneficial as it decreases the 
size of the tumour and downstages it, thereby reducing operative risks such as 
tumour rupture, seeding or nonresectability.2,10,11  The SIOP strategy does not 
influence histology of the tumour despite American concerns that neoadjuvant 
chemotherapy would obscure anaplastic histology.10 
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Chemotherapy drugs used in the SIOP and COG protocols include vincristine, 
actinomycin-D, adriamycin, apirubicin, ifosfamide, carboplatin and etoposide.4  There 
are many chemotherapy drugs that cause renal damage,including ifosfamide, 
cisplatin and cyclophosphamide.12,13 Ifosfamide is included in the management 
protocol for Stage IV nephroblastoma at IALCH and is used for patients with 
remaining metastases after surgery and appropriate treatment.  Some of 
carboplatin’s adverse reactions include renal tubular damage and renal 
insufficiency.13 In the mid 1980s, cyclophosphamide, ifosfamide, platinum compounds 
and etoposide became available.  A review of nephroblastoma cases by Dome et al 
at St Jude Children’s Research Hospital was noted in a paper by Spreafico et al who 
showed that the introduction of cyclophosphamide, ifosfamide, platinum compounds 
and etoposide led to 50–70% disease-free survival rates for children presenting with 
recurrent Wilms’ tumour.14 
Surgical resection follows pretreatment chemotherapy, which has ensured maximal 
tumour size reduction, especially in patients with Stage V nephroblastoma.  In 
patients presenting with bilateral tumours, the surgical aim is to resect all malignant 
tissue whilst leaving enough nephrons to ensure normal renal function; however, in 
patients with bilateral tumours, bilateral total nephrectomy is sometimes necessary, 
resulting in the need for dialysis support until future renal transplantation.4 
Partial nephrectomies are not recommended in patients with unilateral tumours, 
except in selected cases of small tumours that were detected early through routine 
screening.2,4,10  The use of laparoscopic surgery is also not recommended as it is vital 
to explore the whole abdomen and remaining kidney.  The approach is via a large 
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abdominal incision whereby the kidney and tumour are widely excised together with 
the adjacent lymph nodes.11 
Radiotherapy is used in 15% of SIOP-protocol-treated cases.It is always used in 
cases where the tumours were not completely resected, where tumours ruptured, 
where there was lymph node involvement and where nonresectable metastases 
occur after chemotherapy, such as in Stage III and Stage IV nephroblastoma.4 
2.7 ADVERSE EVENTS AFTER NEPHROBLASTOMA MANAGEMENT` 
Despite the fact that the management of nephroblastoma has a high success rate, 
treatment-related adverse events may develop during childhood or even later in life.  
These include orthopaedic presentations, mainly including scoliosis, kyphosis and 
lower back pain as well as short stature, cardiovascular events, including 
hypertension, pulmonary events (if chest radiotherapy was part of management), 
reduction in glomerular filtration rate (GFR), microalbuminuria and second primary 
malignancies.5,15 
Radiotherapy has often been noted as a major risk factor in the development of 
adverse events.  A 2010 study conducted by Van Dijket al5 evaluated the prevalence 
and severity of adverse events in a cohort of 189 long-term nephroblastoma 
survivors.  Sixty-eight percent had suffered at least one or more adverse events.  
Twenty-one percent of the survivors had suffered at least five adverse events.  
Survivors managed with radiotherapy during their treatment were at the highest risk 
for developing an adverse event compared with the non-irradiated survivors.  The 
study observed that out of the entire patient population, the most frequently 
encountered adverse events were orthopaedic events, nephrologic changes and 
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psychosocial events.  Thirteen survivors, of whom 11 were female, presented with 
second tumours.  Eight of these second primary tumours were located within the 
former radiation field or on the border of the radiation field for initial management of 
nephroblastoma. 
Van Dijk further assessed the use of chemotherapy. He documented that the use of 
anthracyclines or alkylating agents increased the risk of cardiovascular events and 
that treatment with alkylating agents increased the risk of developing nephrologic 
adverse events later in life.5  Of all adverse events in the study population, there were 
43 nephrologic adverse events, including glomerular dysfunction, hypertension and 
tubular dysfunction in 123 Wilms’ tumour survivors.  Of these events, hypertension 
was the most frequent, followed by glomerular dysfunction and then tubular 
dysfunction.  Nonspecified nephrologic adverse events were also noted.5  Murat et al 
recently investigated the blood pressure (BP) profile, cardiac diastolic functions and 
pulmonary venous flow in 25 unilateral nephroblastoma patients in remission.  The 
findings were that hypertension and prehypertension were frequent complications in 
nephroblastoma survivors.15 
2.8 RENAL FUNCTION AFTER NEPHRECTOMY 
Patients diagnosed with Wilms’ tumour will undergo a surgical procedure for removal 
of the tumour.  In patients with unilateral disease, this implies unilateral total 
nephrectomy. In bilateral disease, the extent of resection is dependent on the tumour 
size, its position within the kidney and its histology. It is known that patients who have 
been managed for unilateral Wilms’ tumour develop structural and functional 
changes in the remaining kidney.3 
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It is noted that patients who have undergone nephrectomy, chemotherapy and in 
particular radiation therapy to the remaining kidney are at risk of developing impaired 
renal function.3,6  Irradiation may cause radiation nephritis,which causes impairment 
of renal function.16  Renal failure – where the need for dialysis and or renal 
transplantation occurs, is an adverse outcome somewhat unique to Wilms’ tumour 
survivors.  This is primarily seen in patients with bilateral syndromic Wilms tumours 
which include the Denys Drash syndrome and other syndromes involving mental 
retardation.  Non-syndromic Wilms’ tumour populations have a smaller risk of less 
severe degrees of renal dysfunction.17 
In patients managed for nephroblastoma, there are concerns regarding the functional 
impairment of the remaining kidney; however, data are limited regarding the effects 
of treatment for Wilms’ tumour on remnant renal tissue.6 
Cozzi et al18 recently investigated a large cohort of 72 children undergoing treatment 
for unilateral renal tumour (URT) and their renal function adaptation up to the fifth 
decade after treatment.  Renal function was assessed using estimated glomerular 
filtration rate (eGFR).  The results showed that 78% of patients between the ages of 
33 and 51 years had mild to moderate renal functional impairment and that patients 
between 45 and 54 years presented a mean eGFR significantly lower than the 
expected physiological renal function of that age group.  In addition, a high 
prevalence of children having undergone nephrectomy for URT experienced mild 
renal function loss in the second decade of life.18  A study by Bailey et al6 investigated 
the prevalence and nature of renal toxicity in survivors among children treated for 
Wilms’ tumour.  The authors were, however,unable to identify the specific effect of 
different components of treatment in the development of renal impairment, but they 
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did document that concern was needed regarding the potential damage to the 
surviving kidney in patients managed for nephroblastoma.6 Twenty to 40 percent of 
children with unilateral Wilms’ tumour treated with nephrectomy present with renal 
dysfunction (defined as GFR less than the reference range of healthy individuals with 
two kidneys, i.e. 90 ml/min/1.73 m2).19  A 2013 review by Green stated that the risk of 
End Stage Renal Diseas (ESRD) 20 years after diagnosis of unilateral, non-
syndromic Wilms rumour was 0.7%, with a greater prevalence of less severe renal 
dysfunction based on GFR and or the presence of microalbuminuria in 13.8% of 
survivors who received abdominal irradiation as part of their management, and 
11.1% in survivors who did not receive radiotherapy.17 
Hyperfiltration occurs in patients who have a single kidney remaining as a result of a 
disproportional increase in function over structural changes of the kidney.  This may 
result in permanent renal damage.3   Hyperfiltration is suggested by increased single-
kidney GFR as well as proteinuria.  Clinical and experimental data have suggested 
that sustained hyperfiltration in the remnant nephrons results in progressive 
glomerular damage.  This damage increases proportionately to the amount of renal 
tissue removed and the duration of exposure to hyperfiltration.20   BP is also 
increased due to the remnant kidney compensating for the loss of function by 
increasing its workload.3,21  A small increase in blood pressure has been associated 
with unilateral nephrectomy patients using ambulatory blood pressure monitoring.21 
An increase in a patient’s GFR after a dietary protein load is a reflection of the 
existence of the renal functional reserve (RFR) of the kidney.  Hyperfiltration is 
associated with a loss of RFR, and thus the use of protein stimulation of the GFR has 
previously been used to identify patients at risk of developing renal damage.3 Studies 
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assessing renal function after Wilms’ tumour management have indicated that tubular 
function as well as GFR is altered.  It is therefore important not only to use GFR as 
an indication of renal function but also to assess tubular function.3 
In patients with Stage V nephroblastoma, treatment is aimed at preservation of renal 
tissue and function.  Children with bilateral nephroblastoma often require removal of 
more than 50% of their renal mass, placing them at an increased risk for renal 
failure.20  The inclusion of radiotherapy may contribute further to impaired renal 
function in such patients.16, 17 A study by Saarinen-Pihkala et al described the renal 
function of three patients managed for bilateral Wilms’ tumour in whom kidney-
sparing surgery was used after preoperative chemotherapy.  No radiotherapy was 
used in these patients, and the resulting renal function was normal in terms of GFR 
and serum creatinine and urea, and although these numbers are very small, they 
suggest that irradiation may be a major contributor to impaired renal function in 
patients with bilateral tumours.16 
2.9 RECURRENCES OF NEPHROBLASTOMA 
Approximately 15% of patients with favourable histology nephroblastoma and 50% of 
patients with unfavourable histology nephroblastoma experience recurrences or 
relapses.  Most recurrence develops within two years of diagnosis; however, one 
cannot exclude the risk of relapses occurring later.  Relapse in the lungs and pleura 
account for 50–60% of all relapses, with abdominal relapse representing only 30% 
and all other sites, including brain and bone, making up 10–15% of all cases.14 
Prognostic indicators have been assessed for both SIOP and COG (previously 
NWTS) groups.  SIOP has identified adverse prognostic factors for relapsed 
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nephroblastoma.  These include initial Stage IV disease, unfavourable histology, time 
to recurrence of six months or less after diagnosis and recurrences in multiple organs 
or a previously irradiated field.  The NWTS indicates that time to recurrence is a 
strong predictor of survival,with patients who relapse within five months after 
nephrectomy assumed to have a worse outcome than those who relapse after six 
months.  This protocol also identifies other adverse factors such as unfavourable 
histology, advanced tumour stage and relapse outside the lung.  The NWTS – 5 
concluded that gender was a predictive outcome, with male patients faring worse 
than female patients, and that patients initially treated with two drugs compared to 
three drugs had better prognostic outcomes.  This places emphasis on initial 
treatment being a powerful prognostic factor.14 
2.10 NUTRITIONAL STATUS OF PATIENTS MANAGED FOR 
NEPHROBLASTOMA 
The prevalence of malnutrition in children with cancer ranges from 8%to 60%, 
depending on diagnosis and treatment.22 An association has been described between 
nutritional status and overall prognosis and outcome of patients managed for cancer.  
A study by Donalds et al, cited by Ladas et al,22 indicated that there was a direct 
association between the nutritional status of a patient and the lack of relapse in 
paediatric patients managed for solid tumours.  Children with cancer are vulnerable 
to malnutrition as they have increased nutrient requirements for age appropriate 
growth and neurodevelopment, as well as elevated substrate needs due to the 
disease and its treatment.23 The prevalence of malnutrition at diagnosis and 
throughout therapy in all types of childhood cancers and age groups is unknown due 
to lack of data studied.  Factors which can predict the risk for malnutrition include 
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treatment regimens, age, gender, socioeconomic status, biochemical parametes and 
baseline nutritional status.  A multi-centre study by Zimmermann et al24 found that at 
least half of the children who had cancer and were managed at their institutions with 
chemotherapy and or radiotherapy, were malnourished at least once during their 
treatment.  This multi-centre study showed that nutritional status deteriorates rapidly 
after the initiation of anticancer treatment, and that some patients were malnourished 
for a large portion of their time being managed.  These authors concluded that poor 
nutritional status is negatively associated with therapy-related toxicities and overall 
disease outcome.24 The WHO recommendation for nutritional assessment of children 
and adolescents is a weight for height index.  However children with cancer, 
particularly those with large solid tumours such as nephroblastoma may present with 
a normal weight despite severe malnutrition, due to the contributing mass of the 
underlying tumour.23 
In South Africa, malnutrition in patients is common.  Factors impacting on the 
nutritional status of children managed for nephroblastoma and in general include 
protein energy malnutrition (PEM), human immunodeficiency virus (HIV) status, 
actual food intake, overall food availability and nutrient provision from food.25   
Patients who are malnourished at diagnosis of solid tumours have a poorer survival 
rate compared with well-nourished patients.  This relationship appears to be stronger 
in patients with localised solid tumours than in patients with advanced metastatic 
disease.26   A paper by Israels et al27 assessing the clinical guidelines for the 
management of children with nephroblastoma in a low income setting indicate that 
patients are often severely and acutely malnourished at presentation.  This state of 
malnutrition is associated with more severe chemotherapy-associated toxicity.27    
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Patients who present with nephroblastoma are nutritionally managed to provide for 
growth and development as well as to minimise nutritional depletion due to the side 
effects of treatment regimens and cancer cachexia.28  Nutritional support prevents 
loss of lean body mass, which is a vital part of paediatric oncology management.12  
The majority of South African nephroblastoma patients managed are undernourished 
and present with multiple comorbidities including tuberculosis, HIV, viral infections 
and other recognised secondary primary disease that can compromise diagnostic 
and therapeutic plans.9  
 Cancer specific as well as scientifically based recommendations for children with 
cancer are not yet available.  The primary objective for nutritional intervention in 
children with cancer and therefore nephroblastoma should be the maintenance of 
body stores, the minimisation of wasting as well as promoting appropriate growth, 
development and quality of life.  Energy requirements may be based on available 
published paediatric nutritional guidelines and adapted as required.23 Nutrient 
requirements for infants, children and adolescents with cancer should be determined 
with a thorough assessement of each patient’s presenting nutritional status, disease 
state and treatment course.  The Dietary Reference Intakes (DRIs) for age and 
gender can be used to estimate energy and protein requirements for appropriate 
growth in cancer specific patients.  The DRI’s for protein are tabulated in table 2.3 
below.29 Nutritional requirements for sick children are presented in the table below.  
This guideline does not differentiate among different disease conditions; it is merely a 
general guide to oral nutritional requirements in sick children but would include 
children with cancer.30  The goal of in patients nutritional management is to meet 
dietary targets based on the requirements set out below. 
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Table 2.2: Nutritional requirements for sick paediatric patients compared to the EAR* and RNI** 
for age30 
 
Infants 0–1 year Children > 1 year 
Energy for 
sick patients 
High: 130–150 kcal***/kg****/day 
Very high: 150–220 kcal/kg/day 
High: 120% EAR for age 
Very high: 150% EAR for age 
EAR energy 95–110 kcal/kg/day < 90 kcal/kg/day 
Protein for 
sick patients 
High: 3–4.5 g/kg/day 
Very high: 6 g/kg/day (0–6 months) 
increasing to a maximum of 
10 g/kg/day up to one year 
High: 2 g/kg/day  
RNI protein 1.5–2.1 g/kg/day 1.1 g/kg/day 
Sodium for 
sick patients 
High: 3.0 mmol/kg/day 
Very high: 4.5 mmol/kg/day 
Not documented 
RNI sodium 1.5 mmol/kg/day 1.7 mmol/kg/day 
Potassium 
for sick 
patients 
High: 3.0 mmol/kg/day 
Very high: 4.5 mmol/kg/day 
Not documented 
RNI 
potassium 
1.8–3.4 mmol/kg/day 1.6 mmol/kg/day 
*EAR:estimated average requirement; **RNI:reference nutrient intake 
*** kcal (kilocalories) 
**** kg (kilogram) 
Table 2.3 DRI’s and Adequate Intake (AI) values  
for protein across different age groups29 
Age group Protein (g/kg/day) 
0 – 6 months 1.52 
7 – 12 months 1.2 
1 – 3 years 1.05 
4 – 8 years 0.95 
9 – 13 years 0.95 
14 – 18 years 0.85 
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A good nutritional status is beneficial for patients managed for nephroblastoma 
during treatment and thereafter.  The mid-arm circumference (MAC) is a measure of 
muscle, fat and bone.  It is a good measurement to use in assessing malnutrition in 
children, especially when weight and stature measurements are not reliable, such as 
in cases where tumour mass influences total body weight.  In addition to weight and 
height values, triceps skin-fold measurements are a good indicator of energy 
reserves in children.31  Nutritional support may enhance therapy, decrease 
complications and, hopefully, improve survival.32  The long-term consequences of 
anti-neoplastic therapies has been observed by a cohort done by Bauer et al.23  This 
cohort indicated that survivors of children with neuroblastoma, nephroblastoma, 
Hodgkin’s disease and soft tissue sarcomas were more likely to be underweight in 
the long term.  However the degree of long term was not indicated.23 
2.11 DIETARY PROTEIN AND RENAL FUNCTION 
Dietary protein intake can modulate renal function, and there is an ongoing concern 
that habitual consumption of dietary protein in excess of recommended amounts 
promotes chronic renal disease through increased glomerular pressure and 
hyperfiltration of the kidney.33 
A review by Martin et al33 indicated that a high-protein diet was defined as the daily 
consumption of greater than or equal to 1.5 g/kg/day in adult patients.  However, in 
infants a high protein intake is regarded as 3–4.5 g/kg/day and in children (older 
thanone year), it is known to be 2 g/kg/day actual body weight.9 
In 1923 the relationship between the level of dietary protein and the rates of urea 
excretion was first observed and was further supported in a dog model, in which 
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increased dietary protein intake increased the rate of creatinine and urea excretion in 
the urine due to resultant changes in GFR.  Based on these findings, Van Slyke et al 
demonstrated that renal blood flow was the basis for GFR-mediated changes in 
clearance rates in response to increased dietary protein intake.  Dietary protein 
affects GFR, with both acute and chronic increases in consumption increasing 
GFR.33 
A study by Amore et al34 was conducted on six adult patients with a single kidney 
without overt renal disease and eight healthy controls to determine whether 
hyperfiltration induced by an acute response to an oral protein and water load 
modified the urinary albumin excretion (UAE) in the microalbuminuric range by 
increasing glomerular filter permeability.  Participants were given a 150 g meat-
derived protein bolus and 1 l of water and were followed up one hour and four hours 
later. Investigations included UAE, creatinine clearance and microalbuminuria.  At 
baseline, the participants with one kidney had significantly higher UAE values than 
the controls.  At one-hour follow-up, the UAE values in the single kidney group were 
significantly higher than in the control group (p < 0.002 ) and an increase in 
microalbuminuria levels had occurred. High UAE and low creatinine clearance values 
were maintained over the four-hour observation in participants with one kidney.34  
A study by Stribrna et al35 assessed 19 participants with renovascular hypertension 
and the effect of an acute oral administration of protein (meat snack at 1 g/kg protein) 
on urinary albumin excretion.  Microalbuminuria was recorded in only 31% of the 
patients, and further results indicated that an acute protein load did not increase 
albuminuria; however, a significant increase in creatinine clearance was noted.  This 
study recommended 24-hour urine samples for assessment of microalbuminuria.35 
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The effect of an acute oral protein load (OPL) of 150 g protein on the UAE was 
assessed by Papagalaniset al36 in subjects who had undergone unilateral 
nephrectomy more than 10 years ago (18 participants), in subjects who had 
undergone unilateral nephrectomy less than 10 years ago (21 participants) and in a 
healthy control group (16 participants). Urine samples were collected and assessed 
three hours before and after the OPL.  At baseline, the UAE in participants who had 
undergone a nephrectomy more than 10 years ago was higher than the other two 
groups.  The UAE increased significantly after the OPL in subjects who had 
undergone the nephrectomy less than 10 years ago.  The study also suggested that 
the risk of developing renal insufficiency with a solitary kidney increased in time for 
more than 10 years, with this increase in risk appearing to follow a progressive 
compensatory increase in GFR of the remnant kidney during the early years following 
nephrectomy.36 
Research has therefore been done on the effect of protein on renal function in 
healthy individuals as well as in persons with renal disease and/or solitary kidneys.  
What can be concluded is that high protein provision directly influences GFR and 
thus renal function and that over time, renal function in patients with solitary kidneys 
deteriorates. 
Dietary protein provision in patients with renal failure must be strictly controlled and 
modified according to treatment provided, such as conservative management, 
peritoneal dialysis or haemodialysis. 
Table 2.4 below depicts protein (per kg body weight per day) guidelines for the child 
and adult with chronic renal failure.38 
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Table 2.4: Nutritional guidelines for the child37 and adult with chronic renal failure38,39,40 
Age group Predialysis 
Protein (g/kg/day) 
Peritoneal dialysis 
Protein(g/kg/day) 
Haemodialysis 
Protein (g/kg/day) 
Preterm  2.5–3.0 3.0–4.0 3.0 
0.0–0.5 yrs 1.5–2.1 2.1–3.0 2.1 
0.5–1.0 yrs 1.5–1.8 2.0–3.0 1.5–2.0 
1.0–2.0 yrs 1.0–1.8 2.0–3.0 1.5–1.8 
2.0–puberty 1.0–1.5 1.5–2.0 1.0–1.5 
Pubertal 1.0–1.5 1.4–1.8 1.0–1.5 
Postpubertal 1.0–1.5 1.3–1.5 1.0–1.5 
Adults  0.6–0.75 38 1.339 1.240 
 
One must bear in mind that these guidelines are for patients with diagnosed renal 
failure and should be implemented for long-term correct nutritional management of 
patients with such a diagnosis.  
Patients being treated for nephroblastoma are not usually in renal failure, and they 
have high energy and protein requirements.  Patients who present with 
nephroblastoma in South Africa are usually malnourished.  Nephroblastoma patients 
are managed as oncology patients for whom the nutritional provision depends on 
their nutritional status as well as their needs for growth and development. In a 
retrospective study done by Holzinger et al,25  37 nephroblastoma patients’ nutritional 
management and their response to appropriate clinical nutrition were assessed.  The 
median age of the patient population was 47.5 months, with the median daily protein 
provision being 64.6 g.25  This study demonstrated that early aggressive nutritional 
support and frequent nutritional assessments were beneficial to patients with 
nephroblastoma, with nutritional status being enhanced by the nutritional 
interventions used in the study. 
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Potential kidney damage is difficult to assess and quantify and the probability of the 
potential becoming actual is uncertain.  In adult and paediatric patients without 
kidney failure, the recommended dietary reference intakes are applicable.41 
2.12 CONCLUSION 
Patients presenting with nephroblastoma require intense medical management, 
including surgical resection, pre- and post operative chemotherapy as well as 
possible radiotherapy.  Impaired nutrition has an important impact on the overall 
survival and prognosis of this patient population. 
Many aspects of the management of nephroblastoma may contribute to renal 
impairment in Wilms’ tumour patients, and it can be seen that patients who have 
been managed for nephroblastoma have sub-optimal amounts of kidney tissue.  
Patients with a solitary kidney develop hypertrophy of the remaining kidney in an 
attempt to compensate for the workload of the kidney that was surgically removed. 
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CHAPTER 3: METHODOLOGY 
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3.1 RESEARCH AIM 
To determine the renal handling of a once-off bolus dietary protein load in patients 
treated for nephroblastoma   
3.1.1 Conceptual Framework 
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3.2 SPECIFIC OBJECTIVES 
The objective of the study was to assess the following:  
 The effect that the ingestion of a once-off bolus dietary protein load had on 
patients managed for nephroblastoma in terms of the following: 
 The possible increase in blood urea and creatinine biochemical values. 
 The degree of microalbuminuria. 
 Whether the different stages of nephroblastoma (stages I–V) responded 
differently to the bolus dietary protein load in terms of suspected elevated urea 
and creatinine levels. 
 The effect of maturation status of the patients (pre-/post-pubescent) on the 
renal handling of a once-off bolus dietary protein load. 
 The relationship between the renal handling of a once-off bolus dietary protein 
load and the blood pressure of patients managed for nephroblastoma. 
 The effect of time since diagnosis on the renal handling of a once-off dietary 
protein load. 
 The possible relationship between specific treatment modalities used in the 
management of nephroblastoma and renal handling of a once-off bolus dietary 
protein load. 
3.3 STUDY PLAN 
Study domain: Quantitative 
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Study design: Non-randomised intervention study in which patients served as their 
own control before and after a protein load. 
3.4 STUDY POPULATION 
The study population was gathered from nephroblastoma patients who attended the 
Paediatric Oncology Clinic at IALCH.  This clinic serves all patients who have been 
managed for nephroblastoma in KZN and who attend the clinic as part of routine 
monitoring. Despite the clinic being called the ‘Paediatric Oncology Clinic’, patients 
who are classified as adults are seen here if they have been managed for 
nephroblastoma as children.  The majority of patients who attend this clinic are ethnic 
Africans, with Indian and Caucasian patients being uncommon.  Patients attending 
this clinic reside in rural and urban areas, and one can make the assumption that 
patients attending this clinic generally come from middle- to low-income 
backgrounds.  The service area for this clinic is the whole province of KZN, but 
private patients are not seen at the clinic. Patients who attend this clinic can speak 
either English or Zulu, regardless of their culture. Approximately 4–6 patients who 
have been managed for nephroblastoma are seen at the Paediatric Oncology Clinic 
per week, with approximately 55 patients being followed up at the clinic per year 
during the time of the study.  Data gathering occurred from May to November 2010.  
The aim was to obtain 3 – 4 participants per week for a 4 month period providing a 
population of approximately 48 – 55 participants. This target was not achieved in four 
months, hence data gathering was extended to seven months to enlargen the study 
population as much as possible. 
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3.5 SAMPLING STRATEGY 
All patients who attended the clinic and had been managed for nephroblastoma were 
approached by the primary researcher together with an interpreter (if required).  
Those who met the inclusion criteria were asked to participate in the study. 
3.6 INCLUSION AND EXCLUSION CRITERIA 
3.6.1 Inclusion Criteria 
 Patients of any age, ethnicity and gender who had been managed for 
nephroblastoma and who attended their clinic appointments. 
 Patients who had undergone some degree of nephrectomy and/or 
chemotherapy and/or radiotherapy in their treatment for nephroblastoma. 
 Patients who provided written informed consent. 
 Patients who spoke either English or Zulu, or who spoke any other language 
but could communicate with the help of an interpreter and who were willing to 
sign the informed consent form in either English or Zulu. 
3.6.2 Exclusion Criteria 
 Patients managed for nephroblastoma who had consequently had kidney 
transplantation due to renal failure. 
 Patients with Denys-Drash syndrome 
 Patients diagnosed with chronic renal failure. 
3.7 INTERVENTION 
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After baseline blood and urine samples had been taken, participants were provided 
with a bolus dietary protein load of 2 g/kg of their body weight, as 2g/kg exceeds the 
dietary reference intake for children and constitutes a high protein load in both 
paediatrics and adults.30  Nutren Junior ®, a supplement with known protein content 
(Table 3.1), was used in this study.  Protifar ®, a modular protein supplement, was 
added to the standard supplement to reach the required protein load for each 
participant if the amount required exceeded what was provided by 250 ml of Nutren 
Junior.  This additional protein was added by the researcher in each case. The total 
amount of protein required differed among patients and was based on their individual 
weights.  Participants were required to consume the full supplement provided. 
The same supplement was given to adult and paediatric participants. The volume of 
supplement varied depending on the total amount of protein that was required to be 
provided to each patient. The researcher aimed to provide the smallest volume 
containing the correct amount of protein to reduce excessive volumes consumed 
(considered > 500 ml for this study) in older adolescents and adults. This was 
achieved by providing a 250 ml volume of Nutren Junior® supplement enriched with 
sufficient Protifar ® to meet the participants’ requirements. However; more than 
250 ml was required for some participants.42  Table 3.1 provides information 
regarding the protein content of the supplements. 
Table 3.1: Protein provision by Nutren Junior and Protifar42, 43 
Product Volume Proteincontent 
Nutren Junior43 250 ml serving 7.4 g  
Protifar42 5 g scoop 2.2 g 
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Protifar supplement was only added when the calculated required amount of protein 
exceeded what was provided by 250 ml of Nutren Junior. 
After four hours follow-up, urine and blood samples were taken on each participant.  
During this four-hour period, all routine clinical, biochemical and radiological (chest X-
ray and/or abdominal ultrasound) data were gathered.  Throughout this period, 
participants were asked not to eat or drink. However, if young children needed to eat 
within the time frame and it was not possible to wait until after the follow-up blood 
samples, the researcher was informed.  Every effort to ensure that the child did not 
consume a high-protein snack during the testing time period was made so as not to 
influence the results on the follow-up urine and blood tests.  The data of patients who 
did eat during the study (as reported by themselves or their parent/guardian) were 
still gathered and interpreted in the results due to the small study population. 
Clinic appointment times were from 14:00 onwards on a Tuesday, and all participants 
were seen on their scheduled visits to the clinic. No participants were requested to 
attend the clinic on a day other than their appointment day for inclusion in the study. 
3.8 DATA COLLECTION METHODOLOGY 
3.8.1 General Data 
The study took place in the Paediatric Oncology Clinic at IALCH.  Data were 
collected over a six-month period (May 2010– November 2010).  Data were collected 
using a structured data gathering sheet that was developed for the study (Addendum 
6). 
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3.8.2 Data Gathered 
3.8.2.1 Sociodemographic data  
Information was gathering during an interview with the study participants or from their 
hospital files. The following data were collected:  
 Age and date of birth 
 Gender 
3.8.2.2 Nephroblastoma history and management  
The information below was obtained from the patients’ hospital files: 
 Age at diagnosis 
 Stage of disease at diagnosis 
 Treatment protocol  
 Chemotherapy agents, dosages and duration 
 Radiotherapy dosages and duration 
 Surgical resection and degree of kidney resection 
 Comorbidities 
3.8.3 Anthropometrical Data44 
The weight and height of each participant were measured for this study.  The weight 
was required to determine the protein provision required per individual (a pre 
determined 2 g/kg protein bolus).  The height was required for assessing the blood 
pressure of the paediatric participants.  
The primary researcher conducted all anthropometrical measurements on the study 
participants.  All measurements were done using standardised techniques and the 
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equipment described below.  Due to the effect of clothing on the validity of 
measurements, patients were asked to remove any excess layers of clothing to 
reduce measurement error.  All anthropometrical measurements were taken in a 
private room to ensure privacy for the patients. 
3.8.3.1 Weight44,45 
Participants older than two years: 
Weight was measured using a standardised electronic scale: SECA Scale (Volke and 
Halke Hamburg).  The same scale was used throughout the data collection process.  
For children older than two years and adults, weight was measured to the nearest 
0.1 kg.  Weight was measured with the participant standing in the middle of the 
scales platform, without any support.  The weight of each individual needed to be 
equally distributed on both feet.  Weight was measured on arrival of the patients to 
the clinic in the morning of their assessment to reduce diurnal variation.  Patients 
were wearing minimal clothing and no shoes.  One measurement was taken per 
participant 
Participants younger than two years: 
Weight was measured using a SECA 727 electronic pan-type paediatric scale. 
Weight was measured to the nearest 0.01 kg.  If participants were infants, they were 
weighed lying down in the middle of the scale, without clothes, and the weight of their 
diaper was subtracted. One measurement was taken per participant. 
3.8.3.2  Height 44 
Participants older than two years: 
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Standing height was measured using the stadiometer incorporated with the electronic 
scale: SECA Scale (Volke and Halke Hamburg).  The study subjects were barefoot, 
and any head-dressing or head ornaments had been removed before the 
measurement was taken.  The subjects stood with their heels together, arms by their 
sides, legs straight, shoulders relaxed and head in the Frankfort horizontal plane.  
The measurement was taken to the nearest centimetre (cm).  One measurement was 
taken for each participant. 
Participants younger than two years: 
Length was measured using a measuring device with a stationary headboard and a 
moveable footboard, which were perpendicular to the backboard.  Measurements 
were recorded to the nearest 0.1 cm.  Subjects lay in the supine position, with the 
Frankfort plane perpendicular to the backboard.  The subjects’ shoulders and 
buttocks touched the backboard, the legs were straight and the shoulders and hips 
were at right angles to the long axis of the body with the feet flat against the 
footboard.  One measurement per participant was taken. 
The patient population was divided into three sub-groups namely: 0 – 5 years, 5 – 19 
years and > 20 years of age.  The 0 – 5 years and 5 – 19 year age groups 
anthropometrics were assessed according to the WHO growth charts (Addendum 
1)46 
Sub-group 0 – 5 years had gender specific weight for height (W/H) and height for age 
(H/A) assessed to determine if patients were wasted or stunted.  Sub-group 5 – 19 
years were assessed for gender specific Body Mass Index (BMI) for age (BMI/A) to 
Stellenbosch University  http://scholar.sun.ac.za
 
 
35 
 
determine if they were overweight or underweight.  Adults > 20 years of age had their 
BMI assessed to assess if underweight, normal or overweight. 
3.8.4 Biochemical Data 
On admission to the clinic and after signing the informed consent form, participants 
were sent to the phlebotomist and blood specimens were taken for baseline serum 
urea and creatinine analysis.  A 1 ml blood sample was required for the paediatric 
participants and a 5 ml sample for adults.  After four hours, the procedure was 
repeated.  Blood urea and creatinine were compared to the reference values of the 
reporting laboratory. This was situated within the hospital, ensuring immediate 
specimen delivery.  Similarly, spot urine samples for microalbuminurea were taken at 
baseline and after four hours.  The laboratory methods used for biochemical analysis 
are described in Table 3.2 below 
Table 3.2: Analytical methodology of biochemical tests  
Test Analytical methodology 
Urea Urease with GLDH47 
Creatinine Jaffé alkaline picturate, kinetic with blank rate correction48 
Microalbuminuria Polyethylene glycol enhanced immunoturbidimetric method49 
GLDH (glutamate dehydrogenase) 
All urine samples were taken by the primary researcher to the laboratory on each 
data collection day.  The process for microalbuminuria analysis as indicated by 
personal correspondence with the National Health Laboratory Service (NHLS) at 
IALCH is that each urine sample is first assessed with a urine dipstick for the 
presence of protein in the urine. If protein is present, analysis for microalbuminuria is 
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not indicated, and if proteinis not present, microalbuminuria is tested for. Protein in 
the urine is assessed in three categories: 
1+ equivalent to +/- 30 mg/dl or 0.3 g/l 
2+ equivalent to +/- 100 mg/dl or 1 g/l 
3+ equivalent to +/- 300 mg/dl or 3 g/l 
Microalbuminuria is defined as the presence of albumin in the urine at levels that are 
higher than normal but lower than those detected by standard protein dipsticks.1 
 
3.8.5 Clinical Assessment 
All participants (paediatric and adult) were examined by a paediatric surgery registrar 
during their clinic visit, and the following data were recorded in the medical files: 
 Abdominal examination for tumour recurrences (yes/no categories). 
 Interpretation of chest X-ray and ultrasound for tumour recurrence (yes/no 
categories). 
 Blood pressure value. 
 Maturation status (participants were classified as either pre- or post-
pubescent). 
For patients < 20 years, blood pressure was interpreted according to percentile 
charts available: Assessing Blood Pressure for Boys and Girls by Age and Height 
(Addenda 2 and 3).50  This tool is used routinely by the Department of Paediatric 
Surgery at IALCH.  It evaluates diastolic and systolic pressure by age and height and 
classifies the blood pressure into percentiles. For adult patients > 20 years, blood 
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pressure was compared to the norm of 120/80 and was classified as normotensive or 
hypertensive, as detailed in Table 3.3 below. 
Table 3.3:Adult blood pressure criteria51 
Blood pressure Systolic (mmHg) Systolic (mmHg) 
Normotensive 120 80 
Hypertensive ≥ 140 ≥ 90 
mmHg = millimetre of mercury 
3.8.6 Procedure For Data Collection 
On arrival at the clinic, patients were approached by the primary researcher 
regarding participation in the study.  Those patients/parents or guardians of the 
patient who agreed to participate signed an informed consent form. 
Blood samples were taken by the clinic’s phlebotomists for the initial baseline and 
follow-up blood values four hours later.  The volume of blood required for a paediatric 
urea and creatinine blood test was a 1 ml sample and for adults a 5 ml sample.  The 
urine samples required for the microalbuminuria were two single random urine 
samples –one upon admittance into the study, which was the initial baseline sample, 
and the other gathered four hours after the first sample had been provided. Table 3.4 
describes the reference values provided for serum urea and creatinine values 
depending on the age groups of the participants.  The participants’ results were 
compared to the reference value provided by the NHLS for the age of the study 
participants (Table 3.4).  
 
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
38 
 
Table3.4: The difference in urea and creatinine reference values from NHLS analysis 
Age of participants Reference range urea 
(mmol/l) 
Reference range 
creatinine (mmol/l) 
0–12 years 1.8–6.4  27–62 
>13 years 2.1–7.1 44–88 
 
The urine results were analysed according to the results provided by the laboratory, 
described in Section 3.8.4. 
3.8.7 Statistical Analysis 
All data gathered were entered into a database developed by the primary researcher 
on Excel for statistical analysis.  A statistician appointment by SU was consulted for 
data analysis, and the results obtained are given below.  Frequency tables and 
histograms were used to describe the nominal variables. Descriptive statistics were 
used to describe the location parameters such as means and medians, and variation 
parameters such as quartiles and standard deviation were used to describe the 
variation in the data. 
Repeated measures analysis of variance (RMANOVA) was used to determine 
whether there was a significant difference between pre- and post intervention serum 
urea, creatinine and urine microalbumin values. RMANOVA is similar to paired t-tests 
but gives more information about the pre- and post distributions of the variables 
involved. To compare continuous variables versus several groups or treatments, one-
way analysis of variance (ANOVA) was used, and if the residuals were not normally 
distributed, Kruskal-Wallis tests were used. This approach was used to determine 
whether there was a significant effect of the different stages of nephroblastoma in 
response to the dietary protein load. 
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ANOVA for two groups or Mann-Whitney U tests were similarly used to determine 
whether there was a significant effect of the maturation status of patients on the renal 
handling of the population.  These tests were also used to determine the relationship 
of certain chemotherapy agents and the renal function of the population group. 
To compare relationships between two nominal variables, crosstabulation statistics 
with the maximum likelihood chi-square test or Pearson’s chi-square test were used. 
This approach was used to assess the relationship between the nominal responses 
between the effect of the protein load on serum urea, creatinine or urine 
microalbumin protein load and the blood pressure and also to determine whether the 
relationship between high post intervention biochemical values and the time since 
diagnosis was significant.  
ANOVA was used to determine whether the application of post intervention serum 
urea, creatinine and urine microalbumin values had an impact on the time since 
diagnosis. Since the residuals were not normally distributed, the analyses were 
repeated non-parametrically with Mann-Whitney tests. 
3.9 ETHICS APPROVAL 
Ethics approval was sought from the Committee for Human Research, SU 
(NO09/08/222), and the Department of Health, KZN (Reference: HRKM059-10).  All 
participants were clearly informed of the reasons for the study, the procedures they 
or their child would be subjected to as well as the scope of the information required 
by the researcher. 
Participants were informed in either English or isiZulu.  The primary researcher used 
the help of a nursing staff member fluent in isiZulu who was allocated to the clinic 
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every Tuesday over the course of data gathering.  The isiZulu-speaking staff member 
helped the primary researcher with translation from English to isiZulu and isiZulu to 
English if required to facilitate communication between the researcher and 
participants. 
Participants were allocated a study number upon entering into the study, and all data 
gathered were treated as strictly confidential. 
All willing participants and/or their parents or guardians signed informed consent 
forms in either English or isiZulu.  Each participant or their parent or guardian kept a 
copy of the informed consent form, and the primary researcher retained her own 
copy for record purposes.  Children older than seven years of age had to assent to 
participating in the study prior to their enrolment.  Informed consent and assent forms 
are included as Addendum 4 (English) and 5 (isiZulu) respectfully. 
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CHAPTER 4: RESULTS 
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4.1 SAMPLE SIZE 
Thirty-four participants who had been previously managed for nephroblastoma were 
admitted into the study between May and November 2010 and gave their full 
informed consent in either English or isiZulu. 
None were excluded due to the exclusion criteria; however, three patients and their 
parents refused to participate in the study. 
The Centre for Statistical analysis was contacted regarding a power analysis to 
determine the Effect size (Es) of the study population.  The statistical Es between the 
study population of the thesis (N=34) compared to the annual study population of the 
clinic (N= 55), which would have been the maximum size of the study population, had 
data gathering been extended for a full year was assessed.   
For dependent samples (i.e. pre and post intervention values) the Es for N=55 was 
0.447 and for N=34, the Es was 0.574.  For independent samples the Es for N=55 
was 0.624 and for N=34 the Es was 0.8 
Effect sizes of less than 0.6 and at most 0.75 have been recommended by The 
Centre for Statistical Analysis.   Our study therefore had an appropriate Es for 
dependent variables and was lacking in power with independent variables.  
 
4.2 DESCRIPTIVE CHARACTERISTICS OF PARTICIPANTS 
The descriptive statistics of the study population are depicted in Table 4.1. 
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Table 4.1: Descriptive statistics of the study population at baseline 
Variable N Mean Median Minimum Maximum Lower 
quartile 
Upper 
quartile 
Standard 
deviation 
Age (months) 34 92.09 79 24 276 57 120 55.24 
Weight (kg) 34 23.96 19.60 9.60 65.40 17.00 25.40 12.50 
Height (cm) 34 115.83 113.25 85.00 159.00 101.50 124.00 19.54 
Diagnosis age 
(months) 
34 41.06 36.00 10.00 108.00 22.00 56.00 26.68 
Age for metastases 
(months) 
8 46.63 41.00 20.00 68.00 34.50 67.00 18.36 
Radiotherapy 
dosage (Gy) 
14 17.91 15 12 31.50 14.00 15.00 7.39 
Systolic BP 
(mmol/Hg) 
32 106.41 108.5 75.0 159.0 94.5 117.5 16.93 
Diastolic BP 
(mmol/Hg) 
32 56.28 58.0 35.0 76.0 48.0 63.0 10.64 
Time from 
diagnosis to study 
(months) 
34 51.03 33.00 9.0 252.00 18.00 61.00 52.61 
Preingestion urea 
(mmol/l) 
32 4.51 4.35 2.6 8.7 3.6 5.4 1.38 
Preingestion 
creatinine (µmol/l) 
33 64.94 68.0 28.0 98.0 45.0 81.0 20.39 
Preingestion 
microalbumin 
(mg/mmol) 
18 2.89 1.23 0.15 14.94 0.61 3.92 3.61 
N = Number of participants 
 
4.2.1 SocioDemographic Data  
4.2.1.1 Age  
Of the 34 participants who were included in this study, 97% (N = 33) were under the 
age of 20 years and 3% (N = 1) was 23 years of age.  There were two participants 18 
years and older. The majority of patients presenting to the clinic were minors, with 
86% (N =29) of participants being 150 months of age (12.5 years) or younger. 
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4.2.1.2 Gender, race and pubertal status 
Figure 4.1 below illustrates the diversity of the population in terms of race, gender 
and pubertal status (pre- or post-pubescent). 
 
Figure 4.1:The diversity of pubertal status, gender and race of the study population 
The population was relatively evenly distributed in terms of gender, with 53% (N= 18) 
being female.  The majority of the population was pre-pubescent.  Ninety-four 
percent (N= 32) of the study population were ethnic African and 6% (N= 2) were 
Indian. 
No white or coloured participants presented to the clinic during the period of data 
gathering. 
4.2.2 Nephroblastoma History And Management 
4.2.2.1 Age at diagnosis 
The mean age of participants at diagnosis was 41 months, and the median age was 
36 months.  The age of diagnosis varied, with the youngest age at diagnosis being 
10 months and the oldest age being 108 months (nine years). 
0
32
2
16
18
29
5
0 10 20 30 40
White
Black
Indian
Male
Female
Prepubescent
post pubescent
R
ac
e
G
en
d
er
P
u
b
er
ty
St
at
u
s
Number of participants
Number of participants
Stellenbosch University  http://scholar.sun.ac.za
 
 
45 
 
4.2.2.2 Stage of disease at diagnosis 
All stages of nephroblastoma were represented in the study, as seen in Figure 4.2 
below.  Stage II was the predominant stage in this study population, and 20% (N = 7) 
of the study population had been diagnosed with Stage V nephroblastoma. 
 
Figure 4.2: The distribution of study participants amongst the different stages of 
nephroblastoma 
4.2.3 Treatment Protocol 
4.2.3.1 Chemotherapy agents used in the management of nephroblastoma 
Out of the 34 participants, 32 subjects had received chemotherapy and two had not.  
The most commonly used chemotherapy agents were actinomycin-D, vincristine and 
epiadriamycin.  Cisplatin, ifosfamide, carboplatin, etopiside and cyclophosphamide 
were less commonly used therapeutic agents.  Of the 32 participants who had 
received chemotherapy, 28 had completed all the chemotherapy and four had not 
completed the therapy.  Reasons for not completing chemotherapy were not noted 
for this study. 
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The chemotherapies used in the treatment of the participants are illustrated in Figure 
4.3 below. 
 
N = Number of participants 
Figure 4.3: Distribution of chemotherapy agents amongst the study population 
4.2.3.2 Radiotherapy used in the management of nephroblastoma 
Just less than half (N = 14; 41%) of the study population had received radiotherapy 
as part of their medical management.  Five participants (14%) had received lung 
radiotherapy, 12 (35%) had received abdominal radiotherapy and one (3%) had 
received additional radiotherapy to the spine. 
Of the 14 participants (41%) who had received radiotherapy, seven (50% of the 
radiotherapy population) had received a radiotherapy dose of 15 Gy. A relatively wide 
range of radiotherapy dosages had been provided to the 14 participants, ranging 
from 12 Gy (N = 2; 14%) up to 31 Gy (N = 3; 21%). 
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4.2.3.3 Surgical resection in the management of nephroblastoma 
All participants had undergone surgical resection to some degree in the management 
of their nephroblastoma.  Left nephrectomies (N = 19; 55%) were more common than 
right nephrectomies (N = 15;44%). Two (6%)  participants had had a left kidney 
tumorectomy, and four (12%) participants had had a right kidney tumorectomy.  
Therefore, out of the 34 participants, 18% (N = 6) had had a nephrectomy and 
contralateral tumorectomy compared to 82% (N = 28) who had only had a unilateral 
nephrectomy.  None of the participants had had a bilateral nephrectomy. 
4.2.3.4 Prevalence of metastases in the history of management 
Twenty-three percent (N = 8) of the total study population had presented with 
metastases some time during their management or follow-up assessments for 
nephroblastoma. Four (12%) of these participants had had metastases upon initial 
diagnosis, and four (12%) had developed metastases during their treatment or follow-
up phase. 
The age of participants when their metastases developed was between 20 months 
and 68 months.  Two participants (6%) had developed metastases at the age of 68 
months and two (6%) at the age of 41 months. 
Of the different areas assessed for metastases namely lung, brain, bone and regional 
(abdominal including the liver), seven (21%) participants who had metastases had 
developed them in the lung.  Furthermore, three of the seven with metastases to the 
lungs had also developed abdominal metastases (kidney or liver or abdomen). One 
patient (3%) presented with abdominal metastases only. 
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Figure 4.4: The distribution of metastases amongst the study population 
4.2.4 Biochemical Data at Baseline 
Not all the participants had biochemical data for all the biochemical parameters at 
baseline and after the protein load. Although blood samples were taken from all 
participants in the study at baseline and after protein loading, some biochemical 
values were reported by the laboratory as ‘inadequate sample drawn’ or hemolysis. 
Not all urine samples yielded a microalbumin result. Table 4.2 depicts the descriptive 
characteristics of baseline biochemical data. 
Despite not all participants having had conclusive results for all biochemical values, 
all values available were assessed, including incomplete data sets, and analysed for 
descriptive statistics due to the small study population. 
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Table 4.2: Descriptive characteristics of biochemical data at baseline and blood pressure 
Variable N Mean Median Minimum Maximum Lower 
quartile 
Upper 
quartile 
Standard 
deviation 
Reference 
range 
Preingestion urea 
(mmol/l) 
32 4.51 4.35 2.6 8.7 3.6 5.4 1.38 1.8–6.4 
Preingestion 
creatinine (µmol/l) 
33 64.94 68.0 28.0 98.0 45.0 81.0 20.39 27–62 
Preingestion 
microalbumin 
(mg/mmol) 
18 2.89 1.23 0.15 14.94 0.61 3.92 3.61 0–3.5 
Systolic BP 
(mmol/Hg)
  
32 106.4
1 
108.5 75.0 159.0 94.5 117.5 16.93 See 
addenda 
Diastolic BP 
(mmol/Hg) 
32 56.28 58.0 35.0 76.0 48.0 63.0 10.64 See 
addenda 
N = Number of participants 
 
4.2.4.1 Serum urea analysis 
Thirty-two participants (94%) in total had pre ingestion urea results.  Only one (3%) of 
these participants presented with a high urea level before protein ingestion. 
4.2.4.2 Serum creatinine analysis 
Thirty-three (97%) participants had pre-ingestion creatinine values analysed.  Of the 
33 participants, 54% presented with high creatinine pre intervention values, which 
one could interpret as possible baseline renal insufficiency.  However, no patients 
had been clinically diagnosed with renal insufficiency. 
4.2.4.3 Urine microalbumin analysis 
If a participant presented with protein in their urine detected by a urine dipstick in the 
laboratory, the analysis for microalbumin did not occur as per NHLS testing 
standards. 
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Out of the 34 samples of urine provided for preingestion microalbumin, only 18 
samples (53%) were assessed for microalbumin.  Ten of the 34 (29%) participants 
presented with protein in their urine, and six (18%) of the 34 results came back with 
microalbumin not being detected.  Of the 18 samples assessed for microalbumin, 
33% (N = 6) had a high microalbumin value at baseline.  Therefore, 16 participants 
presented with protein or a high microalbumin level in their urine at baseline. This 
could possibly indicate the presence of renal impairment in a portion of the study 
population prior to intervention.  Table 4.7 describes the before- and after-
intervention prevalence of protein and microalbumin in the participants’ urine 
samples. 
4.2.5 Clinical Data 
4.2.5.1 Blood pressure 
The blood pressure of each participant was assessed by the primary researcher 
according to percentile charts used for BP for boys and girls by age and height  
(Addendum 2, 3).    Adult participant blood pressure was compared to adult blood 
pressure criteria, as stipulated in Table 3.3.  The descriptive statistics are highlighted 
in Table 4.1.  In this study, patients were classified as normotensive, prehypertensive 
or hypertensive as per their blood pressure category.  However, this was not a 
confirmed medical diagnosis of the hypertensive state of participants but was merely 
a classification for the purpose of the study. 
Thirty-two (94%) of the 34 participants had their blood pressure taken and assessed. 
The reasons for two participants not having BP taken by the clinic are unknown.  
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Fifty percent (N = 16) of the population presented with normal blood pressure at their 
clinic visit.  Twenty-five percent (N=8) had blood pressure values that were classified 
as prehypertensive, and 25 percent (N = 8) had hypertensive values. 
4.2.5.2 Chest X-rays, ultrasounds and computed tomography scans 
During the clinic visits over the duration of data gathering, 32 (95%) of the 34 
participants had a chest X-ray done. One participant (3%) had an abnormal chest X-
ray presentation.  Data gathered only included normal or abnormal radiological 
findings.  Thirty-one participants (91%) had a normal appearance.  Thirty-two 
participants (94%) in total also went for abdominal ultrasound tests.  Thirty 
participants (88%) had a normal ultrasound screen; however, two participants (6%) 
were assessed to have abnormal ultrasound screens.  Only two participants (6%) 
over the whole data-gathering period had surveillance abdominal computed 
tomography (CT) scans. Both these scans were classified as normal. 
4.2.6 Nutritional Status 
Patients’ nutritional status on the day of the study was assessed and results are 
represented below.   
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Figure 4.5: The distribution of the different parameters of nutritional assessment used in the 
study population 
The largest sub-group for nutritional assessment was the 5 – 19 years category, 
followed by 0 – 5 years and then > 20 years of age. 
Table 4.3 below addresses how the study population was distributed amongst the 
WHO nutritional status classification categories. 
Table 4.3: Descriptive data on the nutritional status of the population according to WHO 
charts46  
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In the 0 – 5 years age group, only N=2 (17%) of the participants were moderately 
stunted, with the remainder of the participants having a normal height for age. Only 
one participant in this age group N=1 (8%) was mildly wasted and the rest of the sub-
population well nourished.  No children were severely wasted (< -3 Z score W/H).  
In the 5 – 19 years age group, N=2 (9%) were classified as thin (< -2 BMI/age), 17 
(81%) as normal BMI for age (< + 1, > -1 BMI/age), 1 (5%) as overweight (<+ 2 BMI/ 
age) and 1 (5%) as obese (> +2 BMI/age). 
The one adult (> 20 years ) had a BMI of 20.3 which was classified as normal. 
4.3 RESULTS FROM PROTEIN LOADING  
All participants were provided with a supplement to drink after their baseline bloods 
and urine sample had been taken. This supplement consisted of Nutren Junior 
supplemented with Protifar to meet each participant’s protein supplement provision 
requirement of 2 g/kg.  The mean volume intake of the supplement consumed was 
90%, indicating that the majority of patients did consume the full required supplement 
volume (Table 4.4). The minimum amount of the supplement consumed was 50% of 
the provided volume (N = 4).  However, on average the general consumption of the 
provided supplement was good, with 73% of the study population consuming 100% 
of their supplement. 
Table 4.4: A breakdown of the volume of protein shake drunk by the study participants 
Percentage of protein shake consumed Number of participants (%) 
0–49% 0 (0%) 
50– 74% 6 (18%) 
75–100% 28 (82%) 
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The data of patients who ate additional foodstuffs during the study (as reported by 
themselves or their parent/guardian) were still gathered and interpreted due to the 
small study population.  Information on what they ate is depicted in Table 4.5 below. 
Table 4.5: Information on which study participants had additional foodstuffs to eat during their 
data gathering, reported by themselves or the parent guardian  
Participants who 
consumed additional food 
Food consumed Protein content of the food eaten 
Per 100 g Per packet 
Participant 16 One small packet of Cheese 
Naks (22 g) 
5.0 g 1.1 g 
Participant 20 One small packet of Flings 
crisps (12 g) 
6.6 g 0.8 g 
 
Participants who did not consume their entire supplement were still included in the 
study due to the small number of participants as well as the fact that excluding 
participants who did not complete the supplement was not stipulated in the protocol 
for the study.  Similarly, participants who ate additional foodstuffs during the 
intervention period were also included, and the effect on their overall protein load is 
noted in Table 4.6 below.  As seen in Table 4.6, participants still received between 1 
and 2 g/kg bolus protein load for this study, with most of the population consuming 
2 g/kg protein.  However, the impact of this incomplete data set on study outcomes 
needs to be considered when interpreting results.  If a larger study population were 
available, one could have focused more on including only the participants who 
consumed 100% of their supplement in this study, which might have made the 
observed differences more significant. 
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Table 4.6: A comparison between protein prescribed and provided versus intake for the study 
 
 
Participant Weight 
(kg) 
Protein provided 
from Nutren Junior 
and Protifar to 
meet 2 g/kg 
Volume of 
protein 
shake drunk 
(%) 
Protein 
provided from 
additional 
foodstuffs 
Total 
protein 
intake 
(g/kg) 
1 13.6 27.2 50 0 1.0 
2 18.4 36.8 75 0 1.5 
3 25.4 50.8 70 0 1.4 
4 19 38 100 0 2.0 
5 44 88 75 0 1.5 
6 19.8 39.6 100 0 2.0 
7 17.8 35.6 75 0 1.5 
8 16.1 32.2 100 0 2.0 
9 17.1 34.2 100 0 2.0 
10 25.6 51.2 50 0 1.0 
11 18.8 37.6 100 0 2.0 
12 17 34 100 0 2.0 
13 54.8 109.6 100 0 2.0 
14 45.6 91.2 100 0 2.0 
15 9.6 19.2 100 0 2.0 
16 29.2 58.4 100 1.1 2.04 
17 19 38 100 0 2.0 
18 13.4 26.8 100 0 2.0 
19 18.6 37.2 100 0 2.0 
20 20.4 40.8 100 0.8 2.04 
21 16.4 32.8 100 0 2.0 
22 22.6 45.2 50 0 1.0 
23 19.8 39.6 100 0 2.0 
24 14.2 28.4 100 0 2.0 
25 19.6 39.2 100 0 2.0 
26 22.5 45 100 0 2.0 
27 25 50 100 0 2.0 
28 65.4 98.1 100 0 1.5 
29 23.6 47.2 100 0 2.0 
30 19.6 39.2 100 0 2.0 
31 44.6 88.2 100 0 2.0 
32 16 32 60 0 1.2 
33 27.6 55.2 100 0 2.0 
34 14.7 29.4 50 0 1.0 
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4.4 EFFECT OF PROTEIN LOADING ON STUDY OUTCOMES 
4.4.1 The Effect of a Once-Off Bolus Dietary Protein Load on the Renal 
Handling of Patients Managed for Nephroblastoma  
RMANOVA was used to determine whether there was a significant difference in 
serum urea, creatinine and urine microalbumin levels between pre-and post 
intervention in subjects for whom both pre- and post ingestion data were available for 
each specific variable. 
Ninety-five percent confidence intervals were used to display differences between 
pre- and post intervention means, and a significance level of 5% was used in 
hypothesis testing. 
The resultant repeated ANOVA for the difference in urea indicated that there was a 
significant increase in serum urea levels after protein loading, as seen in Figure 4.6 
below (p < 0.001).  
 
Vertical bars denote 0.95 confidence intervals 
N = Number of participants 
Figure 4.6: Difference between before and after intervention serum urea values 
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Thirty participants (88%) had both pre- and post intervention serum creatinine levels 
available.  There was no significant change in mean serum creatinine level before 
and after intervention (p = 0.095). Values achieved are shown in Figure 4.7. 
 
Vertical bars denote 0.95 confidence intervals 
N = Number of participants 
Figure 4.7: Difference between before-and after-intervention serum creatinine values of the 
population. 
Only 15 values for microalbumin were assessed due to some urine samples not 
being assessed for microalbumin as a result of protein particles being present in the 
urine.  Therefore, only 15 participants (44%) had before- and after-intervention 
microalbumin values available for analysis (analyses using paired t-tests).  This 
differs from descriptive statistics, which describe baseline values, with 18 participants 
(53%) having microalbumin values available for interpretation. 
The mean pre intervention microalbumin value was 2.04 mg/mmolCRT compared to 
the mean post intervention microalbumin value of 2.83 mg/mmolCRT.  Although 
there was a slight increase in the level of microalbuminuria after protein loading, the 
65.7
62
52
54
56
58
60
62
64
66
68
70
72
74
76
Creatinine before
intervention
Creatinine after
intervention
Creatinine 
values (umol/l) 
(N = 30)  
P value 0.095  
 
Stellenbosch University  http://scholar.sun.ac.za
 
 
58 
 
p-value derived from this test was 0.088, indicating that pre- and post intervention 
microalbumin values did not differ significantly. 
 
Vertical bars denote 0.95 confidence intervals 
N = Number of participants 
Figure 4.8: The difference between before- and after-intervention urine microalbumin values of 
the population 
Table 4.7 below indicates the urine analyses amongst the study participants before 
and after intervention. 
Table 4.7: Description of before- and after-intervention urine analyses 
Number of 
participants 
Before intervention 
(N) 
After intervention 
(N) 
Urine samples 
collected 
34 34 
Microalbumin 
detected 
18 (high levels N = 6) 20 (high levels N = 9) 
Protein present in the 
urine 
10 9 
No microalbumin 
detected 
6 5 
N = Number of participants 
  
2.04
2.83
0.5
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2
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3
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Microalbumin before
intervention
Microalbumin after
intervention
Microalbumin 
values 
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(N =15) 
P value 0.088 
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4.4.2 Effect of the Stages of Nephroblastoma on the Response to a Bolus 
Dietary Protein Load 
4.4.2.1 The difference in mean serum urea before and after protein loading 
The mean differences between pre- and post intervention urea values were assessed 
over the different stages of nephroblastoma and are shown in Figure 4.9 below. 
 
 
N = Number of participants 
Figure 4.9:The difference in mean serum urea values before and after intervention according to 
the stages of nephroblastoma  
ANOVA was used to compare the differences between pre- and post intervention 
values over the different stages of nephroblastoma.  If the residuals were not 
normally distributed, Kruskal-Wallis tests were used. 
The Kruskal-Wallis method confirmed the non significant differences over the stages 
as found with ANOVA.  ANOVA yielded a p-value of 0.59 and the Kruskal-Wallis test 
a value of 0.72.  The difference in urea values before and after protein loading 
according to the diagnosis stage was therefore not significant.  The number of 
participants in each stage was, however, very small. 
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4.4.2.2 The difference in mean serum creatinine values before and after 
protein loading 
The difference in mean serum creatinine values before and after intervention in each 
stage of nephroblastoma is shown in Figure 4.10. 
ANOVA yielded a p-value of 0.94, and the Kruskal-Wallis test similarly gave a p-value 
of 0.70, which proved that the relationship between stage of nephroblastoma and 
serum creatinine value was statistically insignificant. 
The pre-protein ingestion creatinine levels were actually higher than the post 
ingestion values (explaining the negative values), but these changes were not 
significant.  It can also be seen that Stage IV participants had the largest mean value 
for differences in creatinine values, being -8.00 though insignificant.  
 
N = Number of participants 
Figure 4.10:The difference in mean serum creatinine values before and after intervention 
according to the stages of nephroblastoma 
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4.4.2.3 The difference in mean microalbuminuria before and after protein 
loading 
There was no significant difference in the difference in mean microalbumin values 
before and after protein loading across the five stages of nephroblastoma (ANOVA 
yielded a p-value of p = 0.46 and the Kruskal-Wallis test one of p = 0.18).  A small 
population of 22 participants was available for this analysis as that was the number of 
participants who had microalbumin values across the different stages of 
nephroblastoma.  As in the case of serum creatinine, stage IV nephroblastoma had 
the biggest but not significant difference between pre- and post intervention mean 
values, as shown in Figure 4.11. 
 
N = Number of participants 
Figure 4.11: The difference in mean urine microalbumin values before and after intervention 
according to the stages of nephroblastoma 
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4.4.3 The Effect of Maturation Status of the Patients on the Renal Handling of 
a Once-Off Bolus Dietary Protein Load  
This objective investigated the effect of maturation status on the difference in mean 
pre- and post intervention urea, creatinine and microalbuminurea levels.  This was 
done to determine whether post-pubescent participants showed a greater difference 
between the before and after mean values compared to prepubescent participants.  
The results are depicted in Table 4.8 below: 
Table 4.8: The statistical relationship between the difference in mean before- and after-
intervention serum urea, creatinine and urinary microalbumin values and pubertal status 
Biochemical 
variable 
investigated 
Mean difference 
before and after 
protein loading 
in prepubescent 
participants 
Mean difference 
before and after 
protein loading 
in post-
pubescent 
participants 
P-value 
Least square 
means 
P-value Mann-
Whitney U test 
Serum urea 
(mmol/l) (N = 29) 
2.29 (N = 24) 1.96 (N = 5) 0.60 0.49 
Serum creatinine 
(umol/l) (N = 30) 
-4.92 (N = 25) 0.20 (N = 5) 0.37 0.10 
Microalbuminuria 
(mg/mmolCRT) 
(N = 22) 
2.5 (N = 20) -7.78 (N = 2) 0.07 0.05 
N = Number of participants 
There was no significant difference between pre- and post-pubescent categories 
when assessing the difference between pre- and post intervention serum urea and 
serum creatinine values.  Values were obtained using Mann-Whitney U tests.  
The difference in mean urine microalbumin values between pre- and post-pubescent 
participants was borderline significant.  This could indicate that post-pubescent 
participants had a significantly larger difference in mean microalbumin values 
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compared to prepubescent participants.  Post-pubescent participants had progressed 
through puberty and thus a large growth spurt in their lives, which might have 
impacted their renal ability to handle a large protein load, hence the large difference 
between before- and after-intervention mean values.  However, one needs to 
interpret this with caution as the size of the post-pubescent group for differences in 
mean microalbumin was considerably smaller than that of the prepubescent group 
(N = 2 compared to N = 20). 
4.4.4 The Relationship between the Renal Handling of a Once-Off Bolus 
Dietary Protein Load and the Blood Pressure in Patients Managed for 
Nephroblastoma  
This objective was assessed using crosstabulation statistics using the maximum 
likelihood (ML) chi-square test, by comparing the results of participants with normal 
blood pressure and those who presented with hypertension or prehypertension in 
terms of the effect on pre- and post intervention serum urea, creatinine and 
microalbuminuria values. 
The results obtained are detailed in Table 4.9 below: 
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Table 4.9: A summary of the participants who were normotensive, prehypertensive or 
hypertensive and who presented with normal or high serum urea and creatinine and 
microalbuminuria before and after intervention 
 
Blood pressure classification  
Normal 
BP 
Prehypertensive Hypertensive 
P-value (Pearson’s chi 
square; ML chi square) 
Serum urea 
Before 
intervention 
(N = 30) 
   0.45 
Normal blood 
value (N = 29) 
13 8 8 
Increased blood 
value (N = 1) 
1 0 0 
After intervention 
(N = 29) 
   0.71 
Normal blood 
value (N = 12) 
7 3 2 
Increased blood 
value (N = 17) 
8 4 5 
Serum creatinine 
Before 
intervention 
(N = 31) 
   0.11 
Normal blood 
value (N = 13) 
8 4 1 
Increased blood 
value (N = 18) 
7 4 7 
After intervention 
(N = 29) 
   0.32 
Normal blood 
value (N = 15) 
8 4 3 
Increased blood 
value (N = 14) 
7 3 4 
Microalbuminuria 
Before 
intervention 
(N = 17) 
   0.85 
Normal blood 
value (N = 11) 
5 2 4 
Increased blood 
value (N = 6) 
2 1 3 
After intervention 
(N = 19) 
   0.44 
Normal blood 
value (N = 10) 
6 2 2 
Increased blood 
value (N = 9) 
3 2 4 
N = Number of participants  ML = Maximum likelihood 
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There was no statistically significant correlation between the presence of 
hypertension or prehypertension and increases in post ingestion serum urea, 
creatinine or microalbumin values. The sub-population analysed for microalbumin 
was much smaller than those for blood urea and creatinine, and this must be 
considered when interpreting the results. 
4.4.5 The Effect of Time Since Diagnosis on the Renal Handling of a Once-Off 
Bolus Dietary Protein Load 
The statistical relationships between participants who presented with normal or high 
pre- and post intervention serum urea, creatinine and urine microalbumin values and 
their mean time since diagnosis were assessed to determine whether participants 
who presented with high pre- and especially post intervention biochemical values had 
a higher mean time since diagnosis than participants with normal biochemical values. 
All three variables (urea, creatinine and microalbumin) were assessed independently 
using ANOVA and Mann-Whitney tests to determine the relationship between high 
biochemical values before and after protein loading and time since diagnosis.  
ANOVA was used, and statistical significance was set at a p-value of < 0.05.  The 
difference between mean time since diagnosis pre and post intervention and normal 
or high serum urea, creatinine and microalbumin values was not proven statistically 
significant.  The results obtained are described in figures 4.12, 4.13 and 4.14 below. 
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N = Number of participants 
Figure 4.12: The statistical relationship between normal and high before- and after-intervention 
serum urea values and the mean time since diagnosis of the study population 
 
 
N = Number of participants 
Figure 4.13: The statistical relationship between normal and high before- and after-intervention 
serum creatinine values and the mean time since diagnosis of the study population. 
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N = Number of participants 
Figure4.14: The statistical relationship between normal and high before- and after-intervention 
urine microalbumin values and the mean time since diagnosis of the study population 
4.4.6 The Relationship between Specific Treatment Agents Used in the 
Management of Nephroblastoma and the Renal Handling of a Once-Off 
Bolus Dietary Protein Load  
The difference between pre- and post intervention urea, creatinine and microalbumin 
was compared using ANOVA for two groups or Mann-Whitney U tests between 
participants who had received ifosfamide or cisplatin and those who had not. A very 
small subpopulation of the study group had received cisplatin and/or ifosfamide, as 
indicated in figures 4.15, 4.16 and 4.17 below, which should be taken into 
consideration in the interpretation of the results. 
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*ANOVA p = 0.71      N = Number of participants 
^ANOVA p = 0.27 
Vertical bars denote 0.95 confidence intervals 
Figure 4.15: The association between the difference in before- and after-intervention serum 
urea values in participants who had received cisplatin and ifosfamide and those who had not  
No significant relationship was found between participants who had received cisplatin 
and/or ifosfamide with having a larger difference between pre- and post intervention 
serum urea, creatinine and microalbumin values.  The size of the population of 
participants who had received cisplatin and ifosfamide must be considered when 
interpreting these results. 
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*ANOVA p = 0.8     N = Number of participants 
^ANOVA p = 0.26 
Vertical bars denote 0.95 confidence intervals 
Figure 4.16: The association between the difference in before- and after-intervention serum 
creatinine values in participants who had received cisplatin and ifosfamide and those who had 
not  
 
*ANOVA p = 0.7    N = Number of participants  
^ANOVA p = 0.91 
Vertical bars denote 0.95 confidence intervals 
Figure 4.17: The association between the difference in before- and after-intervention in urine 
microalbumin values in participants who had received cisplatin and ifosfamide and those who 
had not 
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CHAPTER 5: DISCUSSION 
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The aim of the study was to determine renal handling of a once-off dietary protein 
load in patients managed for nephroblastoma in terms of the objects set out for the 
study. 
This was a cross-sectional descriptive study conducted at IALCH over a period of 
seven months in 2010.  The descriptive statistics of this study provide some valuable 
insight into the study population.  There were 34 participants included in the study.  
None of the participants included had been diagnosed with renal impairment, 
hypertension or renal failure. 
5.1 THE EFFECT OF A ONCE-OFF BOLUS DIETARY PROTEIN LOAD ON THE 
RENAL HANDLING OF PATIENTS MANAGED FOR NEPHROBLASTOMA IN 
TERMS OF CHANGES IN SERUM UREA, CREATININE AND URINARY 
PROTEIN 
All participants had blood and urine taken for pre- and post intervention serum urea, 
creatinine and urine microalbumin levels. 
A significant increase between pre- and post intervention serum urea values 
occurred, indicating a possible degree of impairment of the renal function in response 
to the dietary protein load; however, there was no significant difference between pre- 
and post intervention serum creatinine values. Despite no significant difference, one 
would expect the post intervention serum creatinine value to be higher than the pre 
intervention value, as with the urea trend, as increased dietary protein intake 
increases the rate of creatinine and urea excretion due to resultant changes in 
GFR.33  However, the mean pre intervention serum creatinine value was higher for 
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the study population than the post intervention value.  This could possibly indicate a 
degree of renal impairment already present in the study population at baseline, but 
further increased post intervention serum creatinine values would then be expected.  
Cozzi et al19 confirmed in 2012 that 20–40% of children with unilateral Wilms’ tumour 
treated with nephrectomy presented with Stage II chronic kidney disease; however, 
such chronic kidney disease was not seen in this study at baseline. 
A very small subpopulation was analysed for the difference between pre- and post 
intervention mean microalbumin values, with no significant change in 
microalbuminuria after intervention.  No studies for nephroblastoma populations on 
this subject could be found, however Green reported that microalbuminuria or 
proteinuria was reported in 0 – 36% of Wilms tumour survivors with an overall 
prevalence of 14.8% in those who received radiotherapy and 7.8% in those who did 
not.  This was seen without patients receiving a high dietary protein load.  This 
degree of presence of microalbuminura was not detected in our study population.17   
However, similar results occurred in a study of 19 patients with renovascular 
hypertension and the effect of a protein load (1 g/kg body weight) on urinary albumin 
excretion.  After administration of that acute protein load, microalbuminuria was 
recorded in 31% of the participants and the study concluded that an acute protein 
load did not increase albuminuria.35 Another study, however; suggested that adult 
patients with a single kidney with reduced renal function reserve presented with a 
significant (p < 0.002) increase in microalbuminuria following oral protein (150 g 
meat-derived protein bolus) and 1 l water load compared to control subjects.  This 
study included six participants and eight controls.34   Perhaps with the present study, 
a significant value would be achieved in a larger study population.  Overall, the study 
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population did not handle dietary protein load as expected, with one expecting to see 
most post intervention values to be higher than pre intervention values, as dietary 
protein affects GFR, with both acute and chronic increases in consumption 
increasing GFR.33 
 
5.2 THE EFFECT OF THE DIFFERENT STAGES OF NEPHROBLASTOMA ON 
THE RESPONSE TO A BOLUS DIETARY PROTEIN LOAD 
This objective determined whether participants from different diagnostic stages of 
nephroblastoma responded differently to the bolus dietary protein load in terms of the 
difference in values of urea, creatinine and microalbuminurea before and after 
intervention.  One would expect participants with Stage IV or V nephroblastoma to 
possibly have a larger difference between pre- and post intervention values, 
considering that these subpopulations often have undergone further surgical 
resections than the other three stages (with Stage V often involving a nephrectomy 
as well as a tumorectomy,i.e. the removal of more renal mass) as well as 
radiotherapy and further chemotherapy agents, which negatively influence renal 
function.12,13,16,17.20  A study published in 2013 by Cozzi et al18 assessed the renal 
function adaptation up to the fifth decade after treatment of children with a unilateral 
renal tumour (not necessarily Wilms’ tumour); the estimated GFR was used to 
measure renal function.  This study showed no significant differences in mean GFR 
between patients treated by three-drug chemotherapy and/or radiotherapy and 
patients treated by nephrectomy and two-drug chemotherapy. Different 
measurements were used compared to the present study; however, the non-
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significant relationship between two- and three-drug chemotherapy and/or 
radiotherapy on renal function is important to note, as it differs from other literature 
that shows the influence of certain chemotherapies and radiotherapy on renal 
function in terms of GFR.18 
Stage I nephroblastoma participants had the largest difference in mean urea values 
before and after intervention, compared to Stage IV nephroblastoma participants who 
had the smallest difference.  The Stage IV nephroblastoma subpopulation had the 
biggest difference between pre- and post intervention mean serum creatinine levels 
as well as microalbumin values, which was expected, but this was not statistically 
significant. 
The different stages of nephroblastoma did not all respond similarly to a bolus dietary 
protein load in terms of a significant difference between pre- and post intervention 
mean urea, creatinine and microalbumin values.  Uniformity in response to the 
dietary protein load across the different stages of nephroblastoma was expected, 
with the difference in mean pre- and post intervention serum urea, creatinine and 
microalbumin values expected to be raised for Stage IV or V nephroblastoma 
patients.  One cannot conclude from the findings that one specific stage of 
nephroblastoma responds more intensely to a dietary protein load compared to 
others, as no statistical relationships have been proven. 
5.3 THE EFFECT OF MATURATION STATUS OF THE PATIENTS ON THE 
RENAL HANDLING OF A ONCE-OFF BOLUS DIETARY PROTEIN LOAD 
This objective was to detect whether post-pubescent participants presented with a 
larger difference between pre- and post intervention biochemical values than 
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prepubescent participants and to determine whether this association was statistically 
significant. 
There was no significant difference between the mean pre- and post intervention 
serum urea and creatinine values in pre- and post-pubescent participants. There was 
a very large yet insignificant difference between the mean pre- and post intervention 
serum creatinine values in the pre-pubescent subpopulation.  This subpopulation was 
much larger than the post-pubescent group. 
Cozzi et al18 found a direct association between aging and increasing number of 
patients with decreased renal function after nephrectomy for unilateral renal tumour 
during childhood.  This study assessed renal functional adaptation up to the fifth 
decade after treatment, which differs from the present study that compared only pre 
and post-pubescent participants, none of which were in their fifth decade after 
treatment. 
The difference in the mean pre- and post intervention microalbumin values in the 
post-pubescent group was of borderline significance (p = 0.05).  This could be 
interpreted as meaning that participants who are post-pubescent and whose kidneys 
have undergone stress during puberty have responded poorly to the dietary protein 
load, with a borderline significantly higher post intervention microalbumin value being 
found.  This may indicate a degree of renal impairment in post-pubescent 
participants, highlighted by their response to a bolus dietary protein load in terms of 
microalbuminurea. This however; was not supported by post-pubescent participants’ 
post intervention serum and creatinine values. 
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There were study limitations affecting this objective. The main problem was that the 
subgroups between pre- and post-pubescent participants were very different, with the 
post-pubescent population consisting of only five participants for urea and creatinine 
and only two participants for microalbumin due to limited microalbumin data.  The 
results should therefore be interpreted with caution. 
 
5.4 THE RELATIONSHIP BETWEEN THE RENAL HANDLING OF A ONCE-OFF 
BOLUS DIETARY PROTEIN LOAD AND BLOOD PRESSURE IN PATIENTS 
MANAGED FOR NEPHROBLASTOMA 
Brenner’s theory indicates that reduced nephron mass leads to hyperfiltration and 
hypertrophy of remaining nephrons, resulting in progressive deterioration of renal 
function with proteinuria and hypertension.52 
Participants who presented with high pre-intervention creatinine and urea values 
(values exceeding the normal range) had a higher prevalence of prehypertension and 
hypertension than participants who had a normal pre-ingestion creatinine and urea 
value. Statistical tests however; proved the association between raised serum 
creatinine and urea values and increased blood pressure statistically insignificant. 
There was a high (50%) but non significant prevalence of hypertension amongst 
participants with a high post intervention microalbumin value.  However, the sub-
population for microalbumin assessment was much smaller than that for urea and 
creatinine, so these results should be interpreted with caution.  A study by Shirzai et 
al52 assessed the serum cystatin, serum creatinine, microalbumin and B2 
microglobulin levels in 24-hour urine and the relation to ambulatory blood pressure 
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parameters of children with a solitary kidney compared to healthy controls.  The 
results showed that children with solitary kidneys had a normal GFR and blood 
pressure but higher urinary microalbumin excretions in long-term follow-up, with a 
significant urinary microalbumin excretion in patients living with a solitary kidney for 
more than five years.  The authors speculate that urinary microalbumin occurred due 
to hyperfiltration in the long run before hypertension developed and GFR decreased.  
This therefore emphasises the need to monitor urinary microalbumin in children with 
solitary kidneys to detect kidney function deterioration before hypertension 
develops.52  The longitudinal progression of chronic kidney disease, and therefore its 
associated hypertension can better be interpreted using serum creatinine, or cystatin 
rather than GFR, and where proteinuria is present, to monitor for progression of renal 
function.17 
5.5 THE EFFECT OF TIME SINCE DIAGNOSIS ON THE RENAL HANDLING OF 
A ONCE-OFF DIETARY PROTEIN LOAD 
This objective wished to determine whether time since medical management affected 
the renal protein handling of the participants and therefore contributed towards the 
overall determination of renal function in these patients. 
The difference between time since diagnosis and pre- and post ingestion normal and 
high urea values was not statistically significant.  The assumption that the longer the 
time since diagnosis and management is the poorer the renal response to a dietary 
protein load and therefore perhaps the poorer the renal function is cannot be 
confirmed in this study population.  Larger studies in populations elsewhere have 
confirmed deterioration of renal function in a solitary kidney or in patients after 
nephroblastoma management over time.18,52  A Review on the evaluation or renal 
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function after successful treatment for unilateral non-syndromic Wilms tumour 
patients  reviewed 19 studies. Eleven studies including participants who had received 
abdominal irradiation and 8 studies not including participants with abdominal 
irradiation. Their duration of follow up and the percentage of participants with 
proteinuria/microalbuminuria and the percentage with decreased GFR was assessed.  
These reports showed that the longer the median or mean duration of follow up, the 
higher the percentage of patients with proteinuria / microalbuminuria or decreased 
GFR.  However this review did not conclude any direct statistical relationship 
between duration of follow up (i.e. time since diagnosis) and renal function.  The 20 
year cumulative risk of end stage renal disease among syndromic Wilms ranged from 
43 – 83% but the 20 year cumulative risk of less severe degrees of renal dysfunction 
among non-syndromic Wilms’ was classified as small.17  
5.6 THE RELATIONSHIP BETWEEN SPECIFIC TREATMENT AGENTS USED IN 
THE MANAGEMENT OF NEPHROBLASTOMA AND THE EFFECT ON   
RENAL HANDLING OF A ONCE-OFF BOLUS DIETARY PROTEIN LOAD 
The researcher set out to determine whether participants who had received cisplatin 
or ifosphamide in their medical management would demonstrate a greater difference 
between pre- and post intervention creatinine, urea and microalbumin values than 
those participants who had not received these agents.  This investigation was based 
on the assumption that participants who had received renal toxic chemotherapy 
agents and abdominal radiotherapy would have a poorer renal response to a large 
dietary protein load than those who had not received renal toxic chemotherapy or 
radiotherapy.5,12 This relationship could not be confirmed in the study population as 
the difference failed to reach statistical significance.  However, it can be seen that 
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often the overall mean difference between pre- and post intervention values is larger 
for those who have received ifosphamide or cisplatin than those who have not.  
Similarly, a study assessing renal function adaptation after treatment of children with 
unilateral renal tumours (including but not limited to Wilms’ tumour) over five decades 
found no significant differences in post nephrectomy renal function adaptation 
between patients who did or did not have chemotherapy and/or radiotherapy.18 The 
groups receiving ifosfamide and cisplatin were considerably smaller than the groups 
who did not receive these chemotherapy agents as part of their overall medical 
management for nephroblastoma. 
5.7 LIMITATIONS OF THE STUDY  
There was no control group used in this study.  The use of a control group would 
have allowed for a better comparison of the nephroblastoma population to a study 
population without nephroblastoma.  If controls were used in this study, a matched 
number of controls for the study population would be recommended.  The use of a 
control group was not in the scope of this study. 
The study population was small, resulting in small subpopulation groups for analysis.  
A larger study population may have bigger statistical power to identify significant 
findings. 
The study population assessed (N = 34) was not as diverse as the complete 
population who presents itself to the clinic on an annual basis (it was estimated at the 
time of data gathering that 55 participants attended the outpatient clinic annually).  
Perhaps participants from a wider age range and more diverse ethnic backgrounds 
could have been included if the data gathering had occurred over the entire year. 
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Data sets collected were not always complete for every participant, as reported in the 
methodology and results for biochemical analyses, which might have affected the 
interpretation of the study results.  The result was that for some variables, the sample 
size was smaller than the total study sample. 
Studies looking at long-term renal function in solitary kidneys and after management 
of specific conditions such as Wilms’ tumour may span decades.18  The mean time 
from diagnosis to the current study was 51 months (four years), and the study did not 
assess longitudinal data but made only a cross-sectional analysis.  A longitudinal 
study of the same population group assessing renal function over decades could 
provide a clearer picture than a once-off response to a dietary protein load. 
Not all participants consumed 100% of the required supplementation drink provided 
for the study; however, participants did consume between 1 and 2 g/kg protein, with 
the majority consuming the required volume of their drink.  However, the results of 
this study need to be interpreted with this in mind, and for future studies, analysing 
participants who only consumed 100% of their required shake may improve the 
statistical validity of the results. 
The study did not identify the difference between HIV positive and negative 
participants as well as participants who had TB either during their management or 
during their follow up and therefore during the study intervention.  HIV and TB are 
important contributing factors to the overall morbidity and mortality of patients in 
South Africa, and the knowledge of their influence on the renal function of patients 
managed for Nephroblastoma would have contributed significantly to the findings of 
the study.  The inclusion of HIV and TB involvement in future studies is 
recommended. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
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6.1 CONCLUSIONS 
The aim of the study was to determine the overall renal handling of a once-off dietary 
protein load in patients managed for nephroblastoma. The study was unable to 
statistically prove that participants managed for nephroblastoma had poor renal 
handling of a once-off dietary protein load in terms of the objectives specified. 
More specifically, there was a significant increase between pre- and post intervention 
serum urea values, indicating a possibly impaired renal response of the participants’ 
kidneys to the dietary protein load.  However, no significant difference was noted 
between the pre- and post intervention serum creatinine and urine microalbumin 
values. 
No significant effects were found for the following:  
 The different stages of nephroblastoma and participants’ response to the dietary 
protein load. 
 The effect of maturation status on the renal handling of a protein load in terms of 
participants’ pre- and post intervention serum and urine biochemical values. 
 The renal handling of a once-off bolus dietary protein load and the blood pressure 
of patients managed for nephroblastoma. 
 The effect of time since diagnosis and the response to a protein load in terms of 
pre- and post intervention serum urea, creatinine and urine microalbumin values. 
 The effect of ifosphamide and cisplatin on the response to a dietary protein load. 
  
Stellenbosch University  http://scholar.sun.ac.za
 
 
83 
 
6.2 RECOMMENDATIONS 
It is recommended that a larger and more representative study population be 
assessed and that further tests and indicators be used to determine renal function 
after management of nephroblastoma, especially of a South African population as 
many studies are conducted in first world countries. 
Although this study was unable to prove that participants with nephroblastoma 
presented with renal impairment after receving a large dietary protein load, 
awareness has been created around this study population and its renal function in 
response to a dietary protein load.  Routine follow-up outpatient clinic care should 
include an aspect of assessing baseline renal function (serum urea and creatinine) at 
each visit to develop a longitudinal data set for each patient on how their renal 
function adapts over time as well as to monitor for renal insufficiency if or when it 
presents itself. 
This study was conducted on South African participants and most of them from lower 
socioeconomic backgrounds.  Neither the nutritional status nor the HIV/tuberculosis 
(TB) status of the participants were included, all of which would have further 
implications on the renal function of the participants, as HIV-associated nephropathy 
and malnutrition (including malnutrition associated with HIV and TB) all impact renal 
function negatively.  The reality is that malnutrition, HIV/AIDS as well as TB are 
prevalent in South Africa, and thus these factors should definitely be included in 
further studies if the results are to be compared and perhaps utilised in the South 
African nephroblastoma population. 
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 ADDENDA 
ADDENDUM 1: WHO GROWTH CHARTS 
 Weight for length girls 
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 Weight for height girls 
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 Length / height for age girls 
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 BMI for age girls 
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 Weight for length boys 
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 Weight for height boys 
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 Length / height for age boys 
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 BMI for age boys 
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ADDENDUM 2: BLOOD PRESSURE LEVELS FOR BOYS BY AGE AND HEIGHT 
PERCENTILES 
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ADDENDUM 3: BLOOD PRESSURE LEVELS FOR GIRLS BY AGE AND HEIGHT 
PERCENTILES 
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ADDENDUM 4: INFORMED CONSENT FORMS ENGLISH 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM (ADULTS) 
 
Title:Assessing the renal handling of a dietary protein load in patients managed for Nephroblastoma 
Reference Number: 
Principal Investigator: Claire Goodall 
Address:IALCH Dietetics Department 
Contact Number:031 240 1645 
 
You are being invited to take part in a research project.  Please take some time to read the information 
presented here, which will explain the details of this project.  Please ask the study researcher or 
doctor any questions about any part of this project that you do not fully understand.It is very important 
that you are fully satisfied that you clearly understand what this research entails and how you could be 
involved.  Also, your participation is entirely voluntary and you are free to decline to participate.  If you 
say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw from 
the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the International Declaration of 
Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this study about? 
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This study will try to determine if patients who have had Nephroblastoma and have been treated for it 
run a risk of developing kidney impairment / failure later on in life.  Some chemotherapy drugs and 
radiotherapy can cause serious damage and harm to normal body tissue, including kidney tissue.  
This study wants to determine if a high protein oral intake influences the way the kidney functions as a 
high dietary protein load is presumed to “stress the remaining kidney(s)”.  We hope to be able to see if 
a blood test and a urine test will show us how the kidney is affected by the protein. 
 
Why have you been invited to participate? 
You have been invited to be part of our study as you have had Nephroblastoma and have received 
treatment for the tumor. 
What procedures will be done? 
You will have the same standard tests done as with your routine clinic visits.  These include: 
- Abdominal Ultrasound 
- Chest X-Ray 
- Visit by the Paediatric Surgeons in the Oncology clinic 
- Weight and height 
- Blood pressure 
Additional tests which will be done for the purpose of the study 
- two blood tests (one when you arrive at the oncology clinic and one 4 hours later at an exact 
time given to you by the researcher) 
- two urine tests (one when you arrive at the oncology clinic and one 4 hours later at an exact 
time given to you by the researcher) 
- 2 further body measurements: Arm circumference and triceps skinfold measurement 
You will be asked to drink a Nutritional supplement provided by the researcher.  The total volume of 
supplement provided will have to be consumed by you. 
What will your responsibilities be? 
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Your responsibilities will be to ensure that you are at the Oncology clinic at the appropriate times as 
provided by the researcher for all the necessary procedures. 
 
Will you benefit from taking part in this research? 
You will not benefit directly from this research but by participating in this study, you will be helping us 
gain new knowledge about the possible risks for further kidney problems later on in your and other 
patients’ lives. All information gathered will be included into your clinic file for future reference. 
If you do not agree to take part, what alternatives do you have? 
You will still have your normal clinic appointment at the Oncology clinic.  You will still have procedures 
done as deemed necessary by the attending doctors. 
Who will have access to your medical records? 
Only the main researcher who is a qualified dietician working at the hospital, as well as the attending 
doctors working at the Pediatric Oncology clinic on the day of the appointment will have access to your 
records.  All information collected will be treated as confidential and protected and your identity will 
remain unknown to anybody else. 
 
You will receive a copy of this information and consent form for your own records 
 
Declaration by participant 
By signing below, I ____________________________ agree to take part in a research study entitled: 
Assessing the renal handling of a dietary protein load in patients managed for Nephroblastoma 
I declare that: 
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- I have read or had read to me this information and consent form and it is written in a language with 
which I am fluent and comfortable. 
- I have had a chance to ask questions and all my questions have been adequately answered. 
- I understand that taking part in this study is voluntary and I have not been pressurized to take part. 
- I may choose to leave the study at any time and will not be penalized or prejudiced in any way. 
- I may be asked to leave the study before it has finished, if the study doctor or researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
Signed at _____________________________  on _____________________________ 
 
____________________________________  _______________________________ 
Signature of Participant     Signature of Witness 
 
Declaration by Investigator 
I Claire Goodall declare that: 
- I explained the information in this document to ______________________________________ 
- I encouraged him / her to ask questions and took adequate time to answer them. 
- I am satisfied that he / she adequately understands all aspects of the research, as discussed above 
- I did / did not use an Interpreter (if interpreter was used – to sign the declaration below) 
Signed at _______________________________ on _____________________________ 
 
_______________________________________ ________________________________ 
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Signature of Investigator     Signature of Witness 
 
Declaration by Interpreter 
I _________________________ declare that: 
- I assisted the investigator Claire Goodall to explain the information in this document to 
____________________ using the language medium Isi-Zulu 
- We encouraged him / her to ask questions and took adequate time to answer them 
- I conveyed a factually correct version of what was related to me 
- I am satisfied that the participant fully understands the content of this informed consent document 
and has had all his / her questions satisfactorily answered. 
Signed at _______________________________ on _____________________________ 
 
_______________________________________ ________________________________ 
Signature of Interpreter     Signature of Witness 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM FOR USE BY PARENTS/ LEGAL 
GUARDIANS 
 
Title: Assessing the renal handling of a dietary protein load in patients managed for Nephroblastoma 
Reference Number: NO09/08/22 
Principal Investigator: Claire Garrett  
Address: IALCH Dietetics Department 
Contact Number: 031 240 1645 
 
Your child is being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the researcher 
any questions about any part of this project that you do not fully understand.  It is very important that 
you are fully satisfied that you clearly understand what this research entails and how your child could 
be involved.  Also, your child’s participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you or your child negatively in any way whatsoever.  You 
are also free to withdraw him / her from the study at any point, even if you do initially agree to let him / 
her take part. 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the International Declaration of 
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Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MCR) 
Ethical Guidelines for Research. 
 
 
What is this study about? 
This study will try to determine if patients who have had Nephroblastoma ( the kidney cancer which 
your child has been treated for) and have been treated for it run a risk of developing kidney problems 
or kidney failure later on in life.  Some chemotherapy drugs, and radiotherapy used to treat 
Nephroblastoma can cause serious damage and harm to normal body tissue, including kidney tissue.  
This study wants to see if a once-off high protein oral intake in the form of a nice tasting “milk shake” 
changes the way the kidney functions as a high amount of protein from food is thought to “stress the 
remaining kidney(s)”.  We hope to be able to see if a blood test and a urine test will show us how the 
kidney is affected by the high protein intake. 
 
Why has your child been invited to participate? 
Your child has been invited to be part of our study as he / she has had Nephroblastoma and has 
received treatment for the tumor. 
What procedures will be done? 
Your child will have the same standard tests done as with his previous clinic visits.  These include: 
- Abdominal Ultrasound (known as the “sound test”) 
- Chest X-Ray 
- Visit by the Paediatric Surgeons in the Oncology clinic 
- Weight and height ( this measures how much your child weighs and how tall he/she is) 
- Blood pressure 
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Additional tests which will be done for the purpose of the study 
- two blood tests (one when your child arrives at the oncology clinic and one 4 hours later at an 
exact time given to you by the researcher). 
- two urine tests (one when your child arrives at the oncology clinic and one 4 hours later at an 
exact time given to you by the researcher)  
Your child will be asked to drink a 250ml vanilla flavored Nutritional supplement provided by the 
researcher.  The total volume of supplement provided will need to be drunk by your child.  Your child 
will also be asked not to eat or drink any further food or drink (apart from water) from the time after 
drinking the “milk shake” until the second time the blood is taken.  This will be about a 4 hour period.  
However if your child is very hungry or you feel that he / she must eat something during this time 
period, please inform the researcher regarding your decision. 
What will your responsibilities be? 
Your responsibilities will be to make sure that your child is at the Oncology clinic at the appropriate 
times as provided by the researcher for all the necessary procedures.  If in the unlikely event that 
injury results as a direct consequence of the research, please inform the researcher and paediatric 
oncology clinic immediately. 
Potential risks involved with this study 
As a participant in the study your child will be asked to drink a “milkshake” provided by the researcher.  
There will be a specific amount of protein in this milkshake, which the researcher will provide.  
Depending on the weight of your child, he / she may have to drink a large volume of this shake, which 
may make him / her feel full and perhaps nauseous.  We do not know how your child’s kidneys will 
react to the protein; that is what we are trying to find out by doing this study, however the risk of doing 
damage to his / her kidneys by drinking this once off “milk shake” is incredibly small, as he / she 
currently doesn’t have kidney failure. 
Blood will have to be taken from your child twice.  This may cause a small amount of discomfort, 
however only a small amount of blood is required. 
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Both procedures (drinking the milkshake, and having blood taken) hold very small risks in doing your 
child harm – as described above. 
Please feel free to talk to the researcher if you have any further questions regarding this matter. 
 
Will your child benefit from taking part in this research? 
Your child will not benefit immediately from this research but by participating in this study, he / she will 
be helping us gain new knowledge about the possible risks for further kidney problems later on in his / 
her life.  All information gathered will be included into your child’s clinic file for future reference. 
If you do not agree to allow your child to take part, what alternatives does your child have? 
Your child will still have their normal clinic appointment at the Oncology clinic. He / she will still have 
procedures done as deemed necessary by the attending doctors. 
Who will have access to your child’s medical records? 
Only the main researcher who is a qualified dietician working at the hospital, as well as the attending 
Doctors working at the Pediatric Oncology clinic on the day of the appointment will have access to 
your child’s record.  All information collected will be treated as confidential and protected and your 
identity will remain anonymous. 
 
There is a possibility that study auditors may need to inspect the research records at a given date in 
the future, however your child’s identity will not be compromised. 
There is no monetary reward for your child participating in the study, nor will it cost you anything for 
the child to be in the study. 
You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or 
complaints that have not been adequately addressed by the study researcher. 
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You will receive a copy of this information and consent form for your own records. 
 
 
Assent of Minor (if > 7 years) 
 
I (Name of Child)__________________ have been invited to take part in the above research project. 
- The study dietician / nurse and my parents have explained the details of the study to me and I 
understand what they have said to me 
- They have also explained that my blood will be taken on two occasions and my urine taken on 
two occasions when I am asked to give it 
- I also know that I am free to withdraw from the study at any time if I am unhappy 
- By writing my name below, I voluntary agree to take part in this research project.I confirm that 
I have not been forced either by my parents or doctor to take part. 
 
_________________________________  _________________________ 
Name of Child       Independent Witness 
 
Declaration by parent / legal guardian 
By signing below, I _______________________ agree to allow my child ___________________ who 
is _________ years old, to take part in a research study entitled: Assessing the renal handling of a 
dietary protein load in patients managed for Nephroblastoma 
I declare that: 
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- I have read or had read to me this information and consent form and that it is written in a language 
with which I am fluent and comfortable. 
- If my child is older than 7 years, he / she must agree to take part in the study and his / her ASSENT 
must be recorded on this form (see above). 
- I have had a chance to ask questions, and all my questions have been adequately answered. 
- I understand that taking part in this study is voluntary and I have not been pressurized to let my child 
take part. 
- I may choose to withdraw my child from the study at any time and my child will no be penalized or 
prejudiced in any way. 
- My child may be asked to leave the study before it has finished in the study doctor or researcher 
feels it is in my child’s best interests, or if my child does not follow the study plan as agreed to. 
Signed at (Place) ____________________________on Date: _______________________ 
 
_____________________________   _____________________________ 
Signature of Parent / Legal Guardian   Signature of Witness 
 
Declaration by Investigator 
I Claire Garrett declare that: 
- I explained the information in this document to:______________________________________ 
- I encouraged him / her to ask questions and took adequate time to answer them. 
- I am satisfied that he / she adequately understands all aspects of the research as discussed above 
- I did / did not use an interpreter  
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Signed at (place)________________________________on Date: _______________________ 
 
_______________________________   ________________________________ 
Signature of Investigator     Signature of Witness 
 
Declaration by Interpreter 
I (name) ____________________________ declare that: 
- I assisted Claire Garrett to explain the information in this document to ____________________ using 
the language IsiZulu 
- We encouraged him / her to ask questions and took adequate time to answer them. 
- I conveyed a factually correct version of what was related to me. 
- I am satisfied that the parent / legal guardian fully understands the content of this informed consent 
document and has had all his / her questions answered satisfactorily. 
Signed at (place) ___________________________on Date: _______________________ 
 
___________________________________  ________________________ 
Signature of Interpreter     Signature of Witness 
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ADDENDUM 5: INFORMED CONSENT FORMS ISI-ZULU 
INCWAJANA EQUKETHE ULWAZI OLUPHATHELENE NABANTU ABAZOBAMBA IQHAZA 
KANYE NEFOMU LEMVUME (ABANTU ABADALA) 
 
Isihloko: Ukuhlolwa kwendlela izinso ezikwazi ukumelana ngayo nomthamo wezakhamzimba 
ezingamaphrotheyini atholakala ekudleni kwiziguli ezilashelwa umdlavuza wezinso (Nephroblastoma) 
Inombolo Eyireferense: NO09/08/22 
Umcwaningi Oyinhloko: ClaireGarrett 
Ikheli: IALCH Dietetics Department 
Inombolo Yocingo :031 240 1645 
 
Uyamenywa ukuthi ubambe iqhaza kulo mklamo (iphrojekthi) wocwaningo. Siyacela ukuthi ufundisise 
ulwazi oluqukethwe kule ncwajana ezokuchazela ngemininingwane yalolu cwaningo. Siyacela futhi 
ukuthi ubuze umcwaningi noma udokotela imibuzo mayelana nezinto ongaziqondisisi kahle kulolu 
cwaningo. Kusemqoka kakhulu ukuthi uzigculise ngokuphelele ukuthi uyaqondisisa ukuthi 
luphathelene nani lolu cwaningo kanye nendlela ongazimbandakanya ngayo kulona. Futhi kumele 
uqonde ukuthi ukubamba kwakho iqhaza kulolu cwaningo yinto oyenza ngentando yakho, 
awuphoqelelwe futhi unelungelo eligcwele lokwenqaba ukubamba iqhaza. Uma uthi cha awufuni 
ukubamba iqhaza, lokho ngeke kube nomthelela ongemuhle kuwena. Ungahoxa noma ninikulolu 
cwaningo, noma ngabe ubuvumile ekuqaleni ukubamba iqhaza. 
 
Lolu cwaningo lwamukelwe yiKomidi Lwezocwaningo Oluphathelene Nabantu eNyuvesi yase-
Stellenbosch futhi luzokwenziwa ngokulandela imihlahlandlela kanye nemigomo yokuziphatha 
ngokwenkambiso efanele Yesitatimende Somhlaba saseHelsinki, Imihlahlandlela yaseNingizimu 
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Afrika Yokuziphatha Ngendlela Efanele Kwezokwelapha kanye Nemihlahlandlela Yokuziphatha 
Ngokwenkambiso Efanele Kwezocwaningo yoMkhandlu Wocwaningo Lwezokwelapha. 
 
Ngabe luphathelene nani lolu cwaningo? 
Lolu cwaningo luzozama ukuthola ukuthi kungenzeka yini ukuthi iziguli eziphethwe yi-Nephroblastoma 
(umdlavuza wezinso olashelwe wona) futhi ezilashelwe yona zibe sengozini yokuba nezinkinga 
zezinso noma izinso ezingasebenzi kahle ngokuhamba kwesikhathi. Amanye amakhambi 
angamakhemikhali (imithi yokwelapha umdlavuza) kanye nohlelo lomshini okhipha imisebe yokushisa 
amaseli omdlavuza, okusetshenziselwa ukwelapha umdlavuza wezinso, kungenza umonakalo 
omkhulu futhi kulimaze namathishu omzimba ajwayelekile, kumbandakanya namathishu ezinso. Lolu 
cwaningo lufuna ukuthola ukuthi ngabe ukuphuza kanye nje vo isiphuzo sobisi esishubile (i-“milk 
shake”) esimnandi esinothe kakhulu ngezakha mzimba ezinamaphrotheyini, kuyayiguqula yini indlela 
izinso ezisebenza ngayo njengoba kucatshangwa ukuthi umthamo ophezulu wamaphrotheyini 
ekudleni “ufaka ingcindezi kwi(zi)nso e(zi)sele”.Sinethemba lokuthi sizokwazi ukuthola ukuthi 
ukuhlolwa kwegazi kanye nokuhlolwa komchamo kuyawuveza yini umthelela wokudla okunothe 
kakhulu ngamaphrotheyini ezinsweni. 
 
Kungani umenyiwe ukuthi ubambe iqhaza? 
Umenywe ukuthi ube yingxenye yocwaningo lwethu ngoba uke waphathwa nguMdlavuza Wezinso 
futhi uke wathola ukwelashelwa isigaxa somdlavuza ezinsweni zakho. 
Ukuhlolwa okunjani okuzokwenziwa? 
Uzohlolwa ngendlela efana naleyo oyijwayele ohlolwa ngayo uma uvakashele emtholampilo. Lokhu 
kumbandakanya: 
- Uhlelo lwe-Ultrasound Yesisu(olwaziwa ngokuthi “ukuhlolwa okuphathelene nemisindo”) 
- I-Eksireyi Yesifuba 
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- Ukuvakashela koDokotela Bezingane emtholampilo woMdlavuza 
- Ukuhlolwa kwesisindo sakho kanye nobude bakho  
- Ukuhlolwa komfutho wegazi emzimbeni 
Okunye ukuhlolwa okuzokwenziwa kulolu cwaningo 
- Ukuhlolwa kwegazi kabili (ukuhlolwa kokuqala kuzokwenziwa ngenkathi ufika emtholampilo 
womdlavuza bese okwesibili kwenziwa emva kwamahora ama-4 ngesikhathi osinikezwe 
ngumcwaningi). 
- Ukuhlolwa komchamo kabili (ukuhlolwa kokuqala kuzokwenziwa ngenkathi ufika emtholampilo 
womdlavuza bese okwesibili kwenziwa emva kwamahora ama-4 ngesikhathi osinikezwe 
ngumcwaningi) 
Yiziphi izinto okuzomele zenziwe nguwena? 
Kuzomele wenze isiqiniseko sokuthi uba seMtholampilo womdlavuza ngesikhathi esifanele osinikezwe 
ngumcwaningi, futhi nguyena ozokwenza konke ukuhlolwa okudingekayo. Uma kwenzeka into eyivela 
kancane yokuthi kube khona ukulimala okubangelwe wucwaningo, uyacelwa ukuthi wazise 
umcwaningi kanye nomtholampilo womdlavuza ngokushesha. Uzobe usunikezwa isiphuzo Esinothe 
ngezakhamzimba futhi kubalulekile ukuthi usiphuze sonke leso siphuzo osinikeziwe. Uzocelwa futhi 
ukuthi ungalokothi udle noma uphuze noma yikuphi okunye ukudla noma isiphuzo (ngaphandle 
kwamanzi) kusukela ngesikhathi onikezwe ngaso isiphuzo esinothe ngezakhamzimba kuze kufike 
isikhathi sokudonswa kwegazi kwesibili. Lokhu kuzokwenzeka emva kwamahora ama-4. Uma uzizwa 
ulambe kakhulu noma ubona ukuthi kufanele udle noma uphuze okuthile ngalesi sikhathi, uyacelwa 
ukuthi wazise umcwaningi. 
Ingozi okungenzeka ibe khona kulolu cwaningo 
Njengomuntu obamba iqhaza kulolu cwaningo uzocelwa ukuthi uphuze isiphuzo esishubile esinobisi 
(“i-milkshake”) osinikezwe ngumcwaningi. Kulesi siphuzo ozosinikezwa ngumcwaningi kumomthamo 
okaliwe wamaphrotheyini. Ngokuya kwesisindo somzimba wakho, kungenzeka kudingeke ukuthi 
uphuze umthamo omkhulu walesi siphuzo sobisi esishubile, lokho kungenza ukuthi isisu sakho 
sigcwale kakhulu futhi uzizwe sengathi uzophalaza.Asazi ukuthi kuzokwenzekani kwizinso zakho uma 
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zithola la maphrotheyini; futhi yilokho esizama ukukuthola ngokwenza lolu cwaningo, kodwa yincane 
kakhulu ingozi yokuthi kungaba khona umonakalo owenzekayo ezinsweni zakho emva kokuphuza lesi 
“siphuzo sobisi esishubile” kanye nje vo, ngoba njengamanje awunayo inkinga yokungasebenzi kahle 
kwezinso. 
Kuzodonswa igazi emzimbeni wakho kabili.Lokhu kungenzeka kubangele ukuthi uzwe ubuhlungu 
obuncane emzimbeni, kodwa-ke ungakhathazeki ngoba kudingeka umthamo wegazi omncane nje. 
Buncane kakhulu ubungozi bomonakalo ongadalwa yilokhu okubili okuzokwenziwa kuwena (ukuphuza 
isiphuzo sobisi esishubile, kanye nokudonswa kwegazi) – njengoba kuchaziwe ngenhla. 
Kumele ukhulume ngokukhululeka nomcwaningi uma uneminye imibuzo mayelana nalolu daba. 
Ngabe ukhona umhlomulo ozowuthola ngokubamba iqhaza kulolu cwaningo? 
Awukho umhlomulo ozowuthola ngokushesha emva kwalolu cwaningo kodwa ngokubamba iqhaza 
kulolu cwaningo, uzosisiza ukuthi sithole ulwazi olusha mayelana nobungozi bezinye izinkinga zezinso 
okungenzeka zibe khonangokuhamba kwesikhathi empilweni yakho noma ezimpilweni zabanye 
abantu. Lonke ulwazi oluzotholakala kulolu cwaningo luzofakwa kwifayela yakho yasemtholampilo 
ukuze lusetshenziswe esikhathini esizayo. 
Uma ungavumi ukubamba iqhaza kulolu cwaningo, yikuphi okunye ongakwenza? 
Uzoqhubeka nokunikezwa njengenjwayelo izinsuku okumele uvakashele ngazo emtholampilo 
woMdlavuza. Kuzoqhutshekwa nokuthi kwenziwe kuwena izinhlelo zokukuhlola kanye nokukwepha 
ezibonwa ngodokotela basemtholampilo njengento esemqoka okumele yenziwe. 
Ngubani ozovunyelwa ukubona imininingwane yamarekhodi akho ezempilo? 
Ngumcwaningi omkhulu kuphelafuthi ongungcweti oneziqu ezifanele mayelana nemithetho yokudla 
ukudla okufanele, osebenza esibhedlela, kanye nodokotela abazobe besebenza emtholampilo 
woMdlavuza Wezingane ngosuku lokuvakashela kwakho emtholampilo, abazovunyelwa ukuthi 
babone amarekhodi akho.Lonke ulwazi olutholakele luzoba yimfihlo futhi luzovikelwa futhi akhekho 
omunye umuntu ozonikezwa ulwazi oluqondene nawe futhi akhonjiswe imininingwane yakho. 
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Kungenzeka kudingeke ukuthi abacwaningi bamabhuku aphathelene nalolu cwaningo bahlole 
amarekhodi alolu cwaningo esikhathini esizayo, kodwa-ke ngeke lidalulwe igama lakho. 
Awukho umhlomulo oyimali ozonikezwa labo ababambe iqhaza kulolu cwaningo, futhi ngeke 
ukhokhiswe lutho ngokuba yingxenye yalolu cwaningo. 
 
Ungaxhumana neKomidi Locwaningo Oluphathelene Nabantu ngokushayela le nombolo yocingo 021-
938 9207 uma kukhona okukukhathazayo noma uma unezikhalazo ezingaxazululwanga ngendlela 
efanele ngumcwaningi owenza lolu cwaningo. 
 
Uzonikezwa ikhophi equkethe lolu lwazi kanye nefomu lemvume ukuze uzigcinele kona. 
Isitatimende esiyisifungo esenziwa ngumuntu obamba iqhaza 
Ngokusayinda lapha ngezansi, mina u- ____________________________ ngiyavuma ukubamba 
iqhaza kucwaningo olunesihloko esithi: Ukuhlolwa kwendlela izinso ezikwazi ukumelana ngayo 
nomthamo wezakhamzimba ezingamaphrotheyini atholakala ekudleni kwiziguli ezilashelwa 
umdlavuza wezinso (Nephroblastoma) 
Ngiyaqinisekisa ukuthi: 
- Ngilufundile noma ngilufundeliwe lolu lwazi kanye nefomu lemvume futhi kubhalwe ngolimi 
engilwaziyo futhi engingenankinga nalo.  
- Nginikeziwe ithuba lokubuza imibuzo futhi yonke imibuzo yami iphendulwe ngendlela egculisayo. 
- Ngiyaqonda ukuthi ukubamba iqhaza kulolu cwaningo yinto umuntu azenzela yona ngokuthanda 
kwakhe futhi akekho ongiphoqelelile ukuthi ngibambe iqhaza. 
- Nginelungelo lokuhoxa kulolu cwaningo noma nini futhi lokho ngeke kuholele ekutheni ngihlawuliswe 
futhi kuphulwe amalungelo ami noma ngayiphi indlela. 
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- Kungenzeka ngicelwe ukuthi ngiphume kulolu cwaningo ngaphambi kokuthi luphothulwe, uma 
udokotela wocwaningo noma umcwaningi ebona ukuthi leso senzo singaba nosizo kimina, noma uma 
ngingalulandeli uhlelo locwaningo okuvunyelwane ngalo. 
 
Kusayindwe e _____________________________ mhlaka __________________________ 
 
____________________________________ _______________________________ 
Isiginesha Yomuntu Obamba Iqhaza  Isiginesha Yomuntu Ongufakazi 
 
Isitatimende esiyisifungo esenziwa nguMcwaningi 
Minau-Claire Garrett ngiyaqinisekisa ukuthi: 
- Ngimchazelile u- ______________________________________ulwazi oluqukethwe kule ncwajana. 
- Ngimkhuthazile ukuthi abuze imibuzo futhi ngizinikezile isikhathi esanele sokuthi ngiphendule 
imibuzo. 
- Ngigculisekile ukuthi uyakuqonda konke okuphathelene nalolu cwaningo, njengoba kukhulunywa 
ngakho lapha ngenhla. 
- Ngisebenzise / Angimsebenzisanga uTolika (uma kusetshenziswe utolika – kumele asayinde lesi 
sitatimende esiyisifungo esibhalwe lapha ngezansi 
Kusayindwe e_____________________________mhlaka___________________________ 
 
_______________________________________________________________________ 
Isiginesha Yomcwaningi    Isiginesha Yomuntu Ongufakazi 
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Isitatimende esiyisifungo esenziwa nguTolika 
Mina u-_________________________ ngiyaqinisekisa ukuthi: 
- Ngimsizile umcwaningi u- Claire Garrett ukuchazela u- ____________________ ulwazi oluqukethwe 
kule ncwajana ngisebenzisa ulimi lwesiZulu 
- Simkhuthazile ukuthi abuze imibuzo futhi sizinikezile isikhathi esanele sokuthi siphendule imibuzo 
yakhe 
- Ngimnikeze ulwazi oluyiqiniso futhi oluqondile mayelana nalokho engitshelwe kona 
- Ngigculisekile ukuthi lowo obambe iqhaza ukuqonda kahle lokho okuqukethwe kule ncwajana 
yemvume futhi yonke imibuzo yakhe iphendulwe ngendlela egculisayo. 
Kusayindwe e____________________________mhlaka __________________________ 
 
_______________________________________________________________________ 
Isiginesha kaTolika    Isiginesha Yomuntu Ongufakazi 
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INCWAJANA EQUKETHE ULWAZI OLUPHATHELENE NABANTU ABAZOBAMBA IQHAZA 
KANYE NEFOMU LEMVUME OKUQONDISWE KUBAZALI/ABAPHATHI BENGANE 
ABASEMTHETHWENI 
 
Isihloko:Ukuhlolwa kwendlela izinso ezikwazi ukumelana ngayo nomthamo wezakhamzimba 
ezingamaphrotheyini atholakala ekudleni kwiziguli ezilashelwa umdlavuza wezinso (Nephroblastoma) 
Inombolo Eyireferense: NO09/08/22 
Umcwaningi Oyinhloko:ClaireGarrett 
Ikheli:IALCH Dietetics Department 
Inombolo Yocingo:031 240 1645 
 
Ingane yakho iyamenywa ukuthi ibambe iqhaza kulo mklamo wocwaningo. Sicela ukuthi ufundisise 
ulwazi oluqukethwe kule ncwajana ezokuchazela ngemininingwane yalolu cwaningo. Sicela futhi 
ukuthi ubuze umcwaningi imibuzo mayelana nanoma iyiphi ingxenye yalolu cwaningo ongayiqondisisi 
kahle. Kusemqoka kakhulu ukuthi uzigculise ngokuphelele ukuthi uyaqondisisa ukuthi luphathelene 
nani lolu cwaningo kanye nendlela ingane yakho engazimbandakanya ngayo kulona. Kumele uqonde 
futhi ukuthi ukubamba kwengane yakho iqhaza kulolu cwaningo yinto umuntu azenzela yona 
ngentando yakhe, akekho ophoqelelwe futhi unelungelo eligcwele lokwenqaba ukuthi ingane yakho 
ibambe iqhaza. Uma uthi cha awufuni ukuthi ingane yakho ibambe iqhaza, lokho ngeke kube 
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nomthelela ongemuhlekuwena noma enganeni yakho. Ungayihoxisa ingane yakho kulolu cwaningo 
noma nini, noma ngabe ubuvumile ekuqaleni ukuthi ibambe iqhaza.  
 
Lolu cwaningo lwamukelwe yiKomidi Lwezocwaningo Oluphathelene Nabantu eNyuvesi yase-
Stellenbosch futhi luzokwenziwa ngokulandela imihlahlandlela kanye nemigomo yokuziphatha 
ngokwenkambiso efanele Yesitatimende Somhlaba saseHelsinki, Imihlahlandlela yaseNingizimu 
Afrika Yokuziphatha Ngendlela Efanele Kwezokwelapha kanye Nemihlahlandlela Yokuziphatha 
Ngokwenkambiso Efanele Kwezocwaningo yoMkhandlu Wocwaningo Lwezokwelapha. 
 
 
Ngabe luphathelene nani lolu cwaningo? 
Lolu cwaningo luzozama ukuthola ukuthi kungenzeka yini ukuthi iziguli eziphethwe yi-Nephroblastoma 
(umdlavuza wezinso ingane yakho elashelwe wona) futhi ezilashelwe yona zibe sengozini yokuba 
nezinkinga zezinso noma izinso ezingasebenzi kahle ngokuhamba kwesikhathi. Amanye amakhambi 
angamakhemikhali (imithi yokwelapha umdlavuza) kanye nohlelo lomshini okhipha imisebe yokushisa 
amaseli omdlavuza okusetshenziselwa ukwelapha umdlavuza wezinso kungenza umonakalo omkhulu 
futhi kulimaze namathishu omzimba ajwayelekile, kumbandakanya namathishu ezinso. Lolu cwaningo 
lufuna ukuthola ukuthi ngabe ukuphuza kanye nje vo isiphuzo sobisi esishubile (i-“milk shake”) 
esimnandi esinothe kakhulu ngezakhamzimba ezinamaphrotheyini kuyayiguqula yini indlela izinso 
ezisebenza ngayo njengoba kucatshangwa ukuthi umthamo ophezulu wamaphrotheyini ekudleni 
“ufaka ingcindezi kwi(zi)nso e(zi)sele”.Sinethemba lokuthi sizokwazi ukuthola ukuthi ukuhlolwa 
kwegazi kanye nokuhlolwa komchamo kuyawuveza yini umthelela wokudla okunothe kakhulu 
ngamaphrotheyini ezinsweni. 
 
Kunganiimenyiwe ingane yakho ukuthi ibambe iqhaza? 
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Ingane yakho imenyiwe ukuthi ibe yingxenye yocwaningo lwethu ngoba ike yaphathwa nguMdlavuza 
Wezinso futhi ike yathola ukwelashelwa isigaxa somdlavuza ezinsweni. 
Ukuhlolwa okunjani okuzokwenziwa? 
Ingane yakho izohlolwa ngendlela efana naleyo ehlolwe ngayo nesikhathi esedlule ngenkathi 
ivakashele emtholampilo.Lokhu kumbandakanya: 
- Uhlelo lwe-Ultrasound Yesisu(olwaziwa ngokuthi “ukuhlolwa okuphathelene nemisindo”) 
- I-Eksireyi Yesifuba 
- Ukuvakashela koDokotela Bezingane emtholampilo woMdlavuza 
- Ukuhlolwa kwesisindo sakho kanye nobude bakho  
- Ukuhlolwa komfutho wegazi emzimbeni 
 
Okunye ukuhlolwa okuzokwenziwa kulolu cwaningo 
- Ukuhlolwa kwegazi kabili(ukuhlolwa kokuqala kuzokwenziwa ngenkathi ingane yakho ifika 
emtholampilo womdlavuza bese okwesibili kwenziwa emva kwamahora ama-4 ngesikhathi 
osinikezwe ngumcwaningi). 
- Ukuhlolwa komchamo kabili (ukuhlolwa kokuqala kuzokwenziwa ngenkathi ingane yakho ifika 
emtholampilo womdlavuza bese okwesibili kwenziwa emva kwamahora ama-4 ngesikhathi 
osinikezwe ngumcwaningi)  
Ingane yakho izocelwa ukuthi iphuze isiphuzo esingu- 250ml esinikezwe ngumcwaningi esinongwe 
nge-vanilla futhi Esinothe ngezakhamzimba.Ingane yakho kumele isiphuze sonke leso siphuzo 
esinikeziwe. Ingane yakho izocelwa futhi ukuthi ingalokothi idle noma iphuze noma yikuphi okunye 
ukudla noma isiphuzo (ngaphandle kwamanzi) kusukela ngesikhathi ephuze ngaso isiphuzo 
sobisi“esishubile esinothe ngezakhamzimba” kuze kufike isikhathi sokudonswa kwegazi kwesibili. 
Lokhu kuzokwenzeka emva kwamahora ama-4. Kodwa-ke uma ingane yakho isilambe kakhulu noma 
ubona ukuthi kufanele idle noma iphuze okuthile ngalesi sikhathi, sicela ukuthi wazise umcwaningi 
mayelana nesinqumo sakho. 
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Yiziphi izinto okuzomele zenziwe nguwena?  
Umsebenzi wakho kuzoba ukwenza isiqiniseko sokuthi ingane yakhe iseMtholampilo Womdlavuza 
ngezikhathi ezifanele ozinikezwe ngumcwaningi ukuze kwenziwe konke ukuhlolwa okudingekayo. 
Uma kwenzeka kuba khona ukulimala okubangelwe wucwaningo, okuyinto engavamisile ukwenzeka, 
uyacelwa ukuthi wazise umcwaningi kanye nomtholampilo womdlavuza wezingane ngokushesha. 
Ingozi okungenzeka ibe khona kulolu cwaningo? 
Njengomuntu obamba iqhaza kulolu cwaningo ingane yakho izocelwa ukuthi iphuze isiphuzo sobisi 
esishubile (“i-milkshake”) esinikezwe ngumcwaningi. Kulesi siphuzo esizonikezwa ingane yakho 
ngumcwaningi kumomthamo okaliwe wamaphrotheyini. Ngokuya kwesisindo somzimba somzimba 
wengane yakho, kungenzeka kudingeke ukuthi iphuze umthamo omkhulu walesi siphuzo sobisi 
esishubile, futhi lokho kungenza ukuthi isisu sengane yakho sigcwale kakhulu futhi izizwe sengathi 
izophalaza.Asazi ukuthi izinso zengane yakho zizophatheka kanjani uma zithola la maphrotheyini; 
yilokho esizama ukukuthola ngokwenza lolu cwaningo, kodwa yincane kakhulu ingozi yokuthi kungaba 
khona umonakalo owenzekayo ezinsweni zengane yakho emva kokuphuza lesi “siphuzo sobisi 
esishubile” kanye nje vo, ngoba njengamanje ayinayo inkinga yokungasebenzi kahle kwezinso. 
Kuzodonswa igazi emzimbeni wengane yakho kabili.Lokhu kungenzeka kubangele ukuthi izwe 
ubuhlungu obuncane emzimbeni, kodwa-ke ungakhathazeki ngoba kudingeka umthamo wegazi 
omncane nje. 
Buncane kakhulu ubungozi bomonakalo ongadalwa yilokhu okubili okuzokwenziwa enganeni yakho 
(ukuphuza isiphuzo sobisi esishubile, kanye nokudonswa kwegazi) – njengoba kuchaziwe ngenhla. 
Kumele ukhulume ngokukhululeka nomcwaningi uma uneminye imibuzo mayelana nalolu daba. 
 
Ngabe ukhona umhlomulo ozotholwa yingane yakho ngokubamba iqhaza kulolu cwaningo? 
Awukho umhlomulo ozotholwa yingane yakho ngokushesha emva kwalolu cwaningo kodwa 
ngokubamba iqhaza kulolu cwaningo, ingane yakho izosisiza ukuthi sithole ulwazi olusha mayelana 
nobungozi bezinye izinkinga zezinso okungenzeka zibe khonangokuhamba kwesikhathi empilweni 
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yakhe. Lonke ulwazi oluzotholakala kulolu cwaningo luzofakwa kwifayela yasemtholampilo yengane 
yakho ukuze lusetshenziswe esikhathini esizayo. 
Uma ungavumi ukuthi ingane yakho ibambe iqhaza kulolu cwaningo, yikuphi okunye okumele 
ikwenze? 
Ingane yakho isazoqhubeka nokunikezwa njengenjwayelo izinsuku okumele ivakashele ngazo 
emtholampilo woMdlavuza. Kuzoqhutshekwa nokuthi kwenziwe izinhlelo zokuxilonga nokwelapha 
ingane yakho ezibonwa ngodokotela basemtholampilo njengento esemqoka okumele yenziwe. 
 
 
Ngubani ozovunyelwa ukubona imininingwane yamarekhodi ezempilo engane yakho? 
Ngumcwaningi omkhulu kuphela futhi oyingcweti eneziqu zemfundo efanele mayelana nemithetho 
yokudla ukudla okufanele, osebenza esibhedlela, kanye noDokotela abazobe besebenza 
emtholampilo woMdlavuza Wezingane ngosuku lokuvakashela kwengane yakho emtholampilo, 
abazovunyelwa ukuthi babone amarekhodi engane yakho.Lonke ulwazi olutholakele luzoba yimfihlo 
futhi luzovikelwa futhi akhekho omunye umuntu ozonikezwa ulwazi oluphathelene negama lengane 
yakho. 
Kungenzeka kudingeke ukuthi abacwaningi bamabhuku aphathelene nalolu cwaningo bahlole 
amarekhodi aphathelene nalolu cwaningo esikhathini esizayo, kodwa-ke ngeke lidalulwe igama 
lengane yakho. 
Awukho umhlomulo oyimali ozonikezwa ingane yakho ngokubamba kwayo iqhaza kulolu cwaningo, 
futhi ngeke ukhokhiswe lutho ngokufakwa kwengane yakho kulolu cwaningo. 
 
Ungaxhumana neKomidi Locwanigo Oluphathelene Nabantu ngokushayela le nombolo yocingo 021 
938 9207 uma kukhona okukukhathazayo noma uma unezikhalazo ezingaxazululwanga ngendlela 
efanele ngumcwaningi owenza lolu cwaningo.  
Stellenbosch University  http://scholar.sun.ac.za
 
 
128 
 
 
Uzonikezwa ikhophi equkethe lolu lwazi kanye nefomu lemvume ukuze uzigcinele kona. 
 
 
Imvume Yengane (uma ineminyaka engaphezu kwesi -7) 
 
Mina (Igama Lengane)u-__________________ ngimenyiwe ukuthi ngibambe iqhaza kulo mklamo 
wocwaningo ongenhla. 
- Isikhulu salolu cwaningo esiyingcweti kwezokudla / umhlengikazi kanye nabazali bami 
bangichazelile imininingwane yalolu cwaningo futhi ngiyakuqonda lokho abangichazele kona. 
- Bangichazelile futhi ukuthi igazi lami lizodonswa kabili futhi nomchamo wami uzothwathwa 
amahlandla amabili uma ngicelwa ukuthi nginikele ngawo 
- Ngiyazi futhi ukuthi ngingahoxa noma nini kulolu cwaningo uma kukhona into engangigculisi 
- Ngokubhala igama lami ngezansi, ngiyazivumela ngokuthanda kwami ukubamba iqhaza kulo 
mklamo wocwaningo. Ngiyaqinisekisa ukuthi abazali bami noma udokotela wami 
abangiphoqelelanga ukuthi ngibambe iqhaza. 
 
_________________________________  _________________________ 
Igama Lengane    Ufakazi Ozimele 
 
Isitatimende esiyisifungo esenziwa ngumzali / umphathi wengane osemthethweni 
Ngokusayinda ngezansi, mina u-_______________________ ngiyayivumela ingane yami u-
___________________ oneminyaka engu- _________ , ukuthi abambe iqhaza kucwaningo 
olunesihloko esithi: Ukuhlolwa kwendlela izinso ezikwazi ukumelana ngayo nomthamo 
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wezakhamzimba ezingamaphrotheyini atholakala ekudleni kwiziguli ezilashelwa umdlavuza wezinso 
(Nephroblastoma) 
Ngiyaqinisekisa ukuthi: 
- Ngilufundile noma ngilufundeliwe lolu lwazi kanye nefomu lemvume futhi kubhalwe ngolimi 
engilwaziyo futhi engingenankinga nalo. 
- Uma ingane yami ineminyaka eyisi- 7, kumele ivume ukubamba iqhaza ocwaningweni / futhi 
IMVUME yakhe kumele ibhalwe kuleli fomu (bheka lokhu okubhalwe ngenhla). 
- Nginikeziwe ithuba lokubuza imibuzo futhi yonke imibuzo yami iphendulwe ngendlelaegculisayo. 
- Ngiyaqonda ukuthi ukubamba iqhaza kulolu cwaningo yinto umuntu azenzela yona ngokuthanda 
kwakhe futhi akekho ongiphoqelelile ukuthi ngivumele ingane yami ukuthi ibambe iqhaza. 
- Nginelungelo lokuhoxisa ingane yami kulolu cwaningo noma nini futhi ngeke lokho kuholele ekutheni 
ngihlawuliswe noma kuphulwe amalungelo ami noma ngayiphi indlela. 
- Kungenzeka ikhishwe ingane yami kulolu cwaningo ngaphambi kokuthi luphothulwe uma udokotela 
wocwaningo noma umcwaningi ebona ukuthi leso senzo singaba nosizokuyona, noma uma ingane 
yami ingalulandeli uhlelo locwaningo okuvunyelwane ngalo. 
Kusayindwe e (Indawo) _________________________mhlaka: _______________________ 
 
_____________________________   _____________________________ 
Isiginesha yoMzali / Umphathi WenganeIsigineshaYomuntu Ongufakazi 
Osemthethweni  
 
Isitatimende esiyisifungo esenziwa nguMcwaningi 
Minau-Claire Garrett ngiyaqinisekisa ukuthi: 
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- Ngimchazelile u- ______________________________________ulwazi oluqukethwe kule ncwajana. 
- Ngimkhuthazile ukuthi abuze imibuzo futhi ngizinikezile isikhathi esanele sokuthi ngiphendule 
imibuzo. 
- Ngigculisekile ukuthi uyakuqonda konke okuphathelene nalolu cwaningo, njengoba kukhulunywa 
ngakho lapha ngenhla. 
- Ngisebenzise / Angimsebenzisanga uTolika (uma kusetshenziswe utolika – kumele asayinde lesi 
sitatimende esiyisifungo esibhalwe lapha ngezansi 
Kusayindwe e_____________________________mhlaka___________________________ 
 
_______________________________________________________________________ 
Isiginesha Yomcwaningi    Isiginesha Yomuntu Ongufakazi 
 
 
Isitatimende esiyisifungo esenziwa nguTolika 
Mina u-_________________________ ngiyaqinisekisa ukuthi: 
- Ngimsizile umcwaningi u- Claire Garrett ukuchazela u- ____________________ ulwazi oluqukethwe 
kule ncwajana ngisebenzisa ulimi lwesiZulu 
- Simkhuthazile ukuthi abuze imibuzo futhi sizinikezile isikhathi esanele sokuthi siphendule imibuzo 
yakhe 
- Ngimnikeze ulwazi oluyiqiniso futhi oluqondile mayelana nalokho engitshelwe kona 
- Ngigculisekile ukuthi lowo obambe iqhaza ukuqonda kahle lokho okuqukethwe kule ncwajana 
yemvume futhi yonke imibuzo yakhe iphendulwe ngendlela egculisayo. 
Kusayindwe e____________________________mhlaka __________________________ 
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_______________________________________________________________________ 
Isiginesha kaTolika    Isiginesha Yomuntu Ongufakazi 
  
Stellenbosch University  http://scholar.sun.ac.za
 
 
132 
 
ADDENDUM 6: DATA COLLECTION SHEET 
         
ASSESSING THE RENAL HANDLING OF PATiENTS MANAGED    
                  
      FOR NEPHROBLASTOMA     
         
   General Information     
         
Study Number:    Age:  
< 20 
years 
> 20 
years 
         
Gender: Male Female   Race    
         
                  
   Medical History     
         
Date of Diagnosis:  dd Mm Yy     
         
Age at diagnosis:           
         
   Stage I II III IV V 
Diagnosis of Nephroblastoma:            
         
   High Low     
Risk profile of 
Nephroblastoma:         
         
         
Recurrent Metastases?: Yes No     
         
If yes to the above question       
         
Age of recurrent metastases:         
         
Location of recurrence: lung Brain bone local     
         
                  
  
Medical management for 
nephroblasoma    
         
Chemotherpy: Yes No      
         
Chemotherapy agents: Actinomycin  Vincristine  
         
   Cisplatin    Ifosphamide  
         
   Epirubicin    Carboplatin  
         
   
Etoposid
e    
Cyclophosphamid
e  
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Chemotherapy dosages:       
         
         
Radiotherapy: Yes No      
         
Area of irradiation:  chest abdomen spine    
         
Radiotherapy dosages:       
         
         
Surgery:  Yes No      
         
Surgical resection:  Left nephrectomy  Right nephrectomy  
         
   Left tumorectomy  
Right 
tumourectomy  
         
   bilateral nephrectomy     
         
                  
   Anthropometrical Assessment    
         
Weight:   kg   Height:   m  
         
         
                  
   Current Medical Management    
         
Blood pressure:   /       
         
         
Chest 
XR:  Normal Abnormal      
         
         
Ultrasound: Normal Abnormal      
         
         
CT Scan:  Normal  Abnormal      
         
                  
   Study Logistics     
         
PROTEIN PROVISION SECTION      
         
Weight =
      Kg      
         
         
Protein Provision (2g/kg) required=         
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Volume of Nutren Junior provided:        
         
Protein provision from Nutren Junior:        
         
         
Volume of Protifar provided:         
         
Protein provision from Protifar:         
         
BIOCHEMICAL SECTION       
         
Pre-ingestion U&E    
Post- ingestion 
U&E   
         
Date   Time   Date  Time  
         
Anion gap      Anion gap       
         
Chloride      Chloride       
         
CO2      CO2       
         
Creatinine      Creatinine       
         
Potassium      
Potassiu
m       
         
Sodium      Sodium       
         
Urea      Urea       
         
Pre ingestion urine analysis for microalbuminurea:        
         
Post ingestion urine analysis for microalbuminurea:        
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ADDENDUM 7: HEALTH RESEARCH ETHICS APPROVAL LETTER 
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